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ABSTRACT 
The aqueous extract of rooibos has been used for more than three hundred years since its 
discovery by the indigenous people. Currently, rooibos is gaining popularity in the 
cosmetic industry and incorporation of rooibos extracts in topical cosmetic formulations 
has become a fashionable trend. Both topical and intestinal absorption of rooibos tea were 
investigated. The transport of aspalathin in the unfermented (green) rooibos aqueous 
extracts and aqueous solution of pure aspalathin were studied. 
 
The percutaneous permeation experiments were conducted with vertical Franz diffusion 
cells using human female abdominal skin obtained from patients who underwent 
cosmetic surgery. The green rooibos extract and pure aspalathin solution buffered in 
phosphate buffer system (pH 5.5) were applied to the skin for 12 hours. Samples of the 
permeants were obtained from the receptor fluid phase and from the stratified layers of 
the skin by using the tape-stripping technique and analysed by HPLC.  
 
In vitro intestinal epithelial transport experiments were carried out by using Caco-2 cell 
monolayers, isolated and cultured from human colonic adenocarcinoma cells, in a 
six-well transwell system. The green rooibos extract and pure aspalathin solution 
buffered in phosphate buffer (pH 7.4) were applied on to the cell monolayers and 
incubated for 2 hours. Samples were obtained from the basolateral phase at 
predetermined time intervals and analysed by HPLC. 
 
Less than 0.1 % of the applied dose of aspalathin permeated the skin. Most of the 
permeated aspalathin accumulated in the stratum corneum. Close to 100 % of aspalathin 
was transported across the Caco-2 cell monolayers at a concentration dependent manner. 
Better absorption of aspalathin was observed using the green rooibos extract than with 
 vii 
the pure aspalathin solution across the Caco-2 cell monolayers.  
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ABSTRACT 
The aqueous extract of rooibos has been used for more than three hundred years since its 
discovery by the indigenous people. Currently, rooibos is gaining popularity in the 
cosmetic industry and incorporation of rooibos extracts in topical cosmetic formulations 
has become a fashionable trend. Both topical and intestinal absorption of rooibos tea were 
investigated. The transport of aspalathin in the unfermented (green) rooibos aqueous 
extracts and aqueous solution of pure aspalathin were studied. 
 
The percutaneous permeation experiments were conducted with vertical Franz diffusion 
cells using human female abdominal skin obtained from patients who underwent 
cosmetic surgery. The green rooibos extract and pure aspalathin solution buffered in 
phosphate buffer system (pH 5.5) were applied to the skin for 12 hours. Samples of the 
permeants were obtained from the receptor fluid phase and from the stratified layers of 
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monolayers, isolated and cultured from human colonic adenocarcinoma cells, in a 
six-well transwell system. The green rooibos extract and pure aspalathin solution 
buffered in phosphate buffer (pH 7.4) were applied on to the cell monolayers and 
incubated for 2 hours. Samples were obtained from the basolateral phase at 
predetermined time intervals and analysed by HPLC. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 Taxonomy of Aspalathus linearis 
As early as 1686, Aspalathus linearis (Burm. fil) R. Dahlgren was described by Ray in 
Historia Plantarium as “Genista Africana frutescens, foliis Lineariae angustioribus glaucis, 
flore lutea D. Sherard” (Dahlgren, 1968) and has also been validly known as “Galega 
affinis Malabarica arborescens siliquis majoribus articulatus” by Plukenet in 1700 
(Dahlgren, 1968). Later on, numerous different names were given to A. linearis by several 
botanists and only in 1963, Dahlgren confirmed that the various descriptions were directed 
to the same plant. Together with N.L. Burman who described the plant in the name 
Psoralea linearis Burm. fil in 1768, Dahlgren (1968) made a combination resulting in the 
formally accepted description correctly known as “Aspalathus (subgen. Nortieria) linearis 
(Burm. fil. 1768) R. Dahlgren 1963” (Dahlgren, 1964).  
 
1.2 Botanical description 
Rooibos (Aspalathus linearis) is a shrub-like leguminous flowering plant that belongs to 
the Fabaceae (Leguminosae) family. It naturally inhabits the Cederberg Mountain regions, 
mountains of the Table Mountain series (Dahlgren, 1968), north-west of Cape Town in 
South Africa. The plant can grow up to 2 meters high, bearing slender branches that may 
be sparingly or closely distributed. The bark is ferruginous, dark red or purple on the 
younger branches, becoming grey upon ageing (more than 1½ years) (Dahlgren, 1963 and 
Dahlgren, 1968). Leaves are simple, long and narrow, ranging from 15 to 60 mm long and 
0.4 to >1.0 mm broad. The leaves grow straight, may be slightly flattened and rigid, found 
singly or in bunches. Leaves may range from pale, bright or dull green, rarely light green, 
often becoming reddish-brown when dried (Dahlgren, 1968). Small short lateral teeth may 
occasionally be found at the base of the leaf (Dahlgren, 1963). Flowers are found on the 
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tips of the branches, one or up to seven together in terminal racemes or umbels, or in 
clusters on lateral short shoots (Dahlgren, 1968). The pea-shaped flowers are pale to bright 
yellow often with a touch of purple at the back and base of the petals (Dahlgren, 1963 and 
Dahlgren, 1968). The flowers are produced in spring through early summer (Erickson, 
2003) and each flower generates one fruit referred to as a pod containing only one small, 
hard-shelled, dicotyledonous seed that becomes reddish-brown when ripe (Dahlgren, 1968 
and http://members.tripod.com/~Meerkat_2/erooibos.html). The plant has a tap root system 
that can grow up to 2 m long to enable it to survive during periods of droughts in summer 
(Erickson, 2003). Nodules of nitrogen fixing bacteria, Bradyrhizobium aspalti, are found 
on the root systems that exist symbiotically with the plant (Boone et al., 1999). These 
bacteria absorb atmospheric nitrogen dioxide converting it to biologically useful ammonia 
(Erickson, 2003 and Boone et al., 1999), a process called nitrogen fixation, providing 
nutrients to the plant minimising the need for fertilising commercial crops for nitrogen, and 
in exchange the bacteria acquire their nutrients from the plant generated during 
photosynthesis (Erickson, 2003).  
 
 
Figure 1.1: The natural habitat of Aspalathus linearis in the Cederberg Mountain regions 
(marked in red) north-west of Cape Town in South Africa (picture provided by A.M. 
Viljoen). 
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Figure 1.2: Rooibos plantation (Erickson, 2003). 
 
 
Figure 1.3: The rooibos plant bearing needle-like leaves and pea-shaped flowers on 
ferruginous young branches (photo provided by A.M. Viljoen). 
 
1.3 Variation in the Aspalathus linearis species complex 
There are more than 200 species of Aspalathus indigenous to South Africa (Erickson, 2003) 
and the genus Aspalathus is a type of “sclerophyll bush” commonly called “fynbos” or 
“macchia” (Dahlgren, 1963). A. linearis together with A. pendula R. Dahlgren fall under 
the subgenus Nortieria (Dahlgren, 1968) of the genus Aspalathus. It is the leaf character 
that differentiates the subgenus Nortieria from the rest of the groups of Aspalathus 
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(Dahlgren, 1968). A. linearis is a polymorphic species that comprises three subspecies, 
namely, Aspalathus linearis (Burm. fil.) R. Dahlgren ssp. linearis; Aspalathus linearis 
(Burm. fil.) R. Dahlgr. ssp. pinifolia (Marl.) R. Dahlgren; and Aspalathus linearis (Burm. 
fil.) R. Dahlgren ssp. latipetala R. Dahlgren, each with characteristic morphology and 
geographical distribution. A. linearis ssp. linearis is the most common of the subspecies 
(Dahlgren, 1968), large variation in total size, length and coarseness of leaf, leaf colour etc. 
is present within this subspecies. Many of the commercially available rooibos tea 
plantations originate from wild forms of A. linearis, sometimes referred to as Rooi (Red), 
Rooi-Bruin (Red-Brown), Vaal (Grey), and Swart (Black) types, they are closely related 
and differ only in respect of slightly deviating in style of growth (habit), area of occurrence, 
the colour and aroma of tea they produce, and the quality of the processed product 
(Dahlgren, 1968 and  http://members.tripod.com/~Meerkat_2/erooibos.html). Only the 
Red tea type is cultivated and commercialised (Dahlgren, 1968). Within the Red tea type it 
is further subdivided into two subtypes, namely, (i) Nortier-type, the cultivated and 
selected biotype that originated from the wild forms, has fresh green slender leaves and 
bright yellow flowers that produce reddish-coloured tea with a mild aroma (Dahlgren, 
1968); (ii) Cederberg-type, which also originated from the same wild forms from which the 
Nortier-type was selected but occurs in slightly different regions to the Nortier-type. The 
tea produces the same colour and aroma but is said to be of inferior quality in comparison 
to the Nortier-type (Dahlgren, 1968).  
 
1.4 The history of rooibos tea 
By definition the word “tea” refers to infusions made from leaves of Camellia sinensis (L.) 
Kuntze (Theaceae), the evergreen shrub from which green tea or oolong tea is made. 
Infusions made from herbs like rooibos (Aspalathus linearis) are technically referred to as 
“tisanes”. It has now, however, become accepted to refer to herbal infusions as tea, and 
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rooibos makes a tea that is red-brown in colour hence the name “Rooibos” (meaning 
Redbush) (Erickson, 2003). 
 
The use of rooibos dates back to more than 300 years ago when the indigenous mountain 
inhabitants of South Africa, the Khoisan, a tribe of South African Bushman, discovered 
that the rooibos could be brewed to make a sweet and tasty beverage (Erickson, 2003 and 
Cason, 2004). The use of this plant was then recorded by the botanist Carl Thunberg when 
the tea was introduced by the Khoisan in 1772 (Morton, 1983). Rooibos was collected by 
chopping the young branches of the wild shrubs in the mountains with axes, bruising the 
harvest with wooden hammers and leaving it in heaps to ferment (Dahlgren, 1968 and 
Erickson 2003). Today, the method of harvesting and processing is done in very much the 
same way but with more advanced technology, refined methods with systematic cultivation 
and strict quality control throughout (Erickson, 2003 and http://www.dr-nortier.com/history 
.htm)  
 
Before 1925 the tea was exclusively collected from the wild in the mountains (Dahlgren, 
1963). In 1904, a Russian immigrant Benjamin Ginsberg, whose family was involved in 
the tea industry in Europe for over a century realized the market potential and started to 
buy, pack and trade this “tea” collected in the mountains by the Khoisan. Cultivation of 
rooibos was attempted in about 1925 by Dr. P. le F. Nortier, who was a medical practitioner, 
and Mr. O. Berg who collected seeds in the Cederberg Mountains (Dahlgren, 1963). In the 
1930’s, Dr. Nortier investigated how to collect the seeds effectively, how to improve 
germination, and how to handle the seedlings and grow the shrubs in plantations. Dr. 
Nortier shared his experience with some farmers resulting in rooibos being produced on a 
larger scale (Dahlgren, 1968). Ginsberg then bought the tea from the farmers and traded 
the product globally on a small scale. The demand for rooibos increased dramatically 
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during World War II when the availability of Oriental tea declined due to difficulties 
experienced with buying and shipping tea from war-ridden Asia. However, the rooibos tea 
market underwent a severe crisis in 1948 which resulted in establishing the Clanwilliam 
Tea Cooperative, in an attempt to save the interest of the tea producers. Over-production of 
rooibos tea led to another crisis in 1954, after which the Rooibos Tea Control Board was 
established and stabilised the market once again by improving, controlling and classifying 
the type of rooibos cultivated and marketed (Dahlgren, 1968). 
 
In 1968, Annekie Theron discovered the ability of rooibos tea to calm her baby, relieving 
infant colic and insomnia. It was not until 1970 that rooibos tea became internationally 
recognized (Erickson, 2003 and Cason, 2004) with a book she wrote and published, titled 
Allergies: An Amazing Discovery. Since then she patented a rooibos extract that is now 
used in cosmetic products and started her own line of health and cosmetic products 
(Erickson, 2003). 
 
1.5 Uses and benefits of rooibos 
Rooibos is famous for being naturally caffeine-free (Morton, 1983) making it suitable for 
children, the elderly and people who are intolerant to the stimulative effects of caffeine, 
and its low tannin content (4.4%) minimises the risk of insufficient iron absorption, a 
condition frequently found in tea drinkers that result from iron-tannin complexation 
(Erickson, 2003 and Morton 1983). Rooibos tea also contains various amounts of minerals 
and nutrients (Table 1.1) making it a health beverage ideal to use as a fluid replacement for 
infants and athletes.  
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Table 1.1: Nutritional content of Rooibos tea (Morton, 1983). 
Nutrient Amount 
Caffeine 0 
Ascorbic acid 15.7mg/100g 
Tannin (as gallic acid) 4.4% 
Protein 6.9% 
Ash 2.5% 
Soluble ash 1.3% 
Petroleum ether extract 1.7% 
Iron 0.33% 
Alumina 0.99% 
Calcium 0.20% 
Magnesium 0.33% 
Potash 0.56% 
Sulphate 0.11% 
Manganese 0.012% 
Phosphate 0.12% 
 
Before Annekie Theron discovered the effects of rooibos tea on her baby, rooibos tea was 
purely a good-tasting beverage enjoyed by the people who discovered it (Erickson, 2003). 
After having found no documentation on the uses and benefits of rooibos tea she began her 
own experiments with local babies who had colic and allergies. A series of health claims 
for rooibos tea were then made and published including, among others, digestive disorders 
as in infant colic and stomach upsets, allergies such as hay fever, asthma, skin allergies, 
eczema and nappy rash, sleep disorders, headaches and migraine by calming the central 
nervous system (http://www.rooibosltd.co.za/ and http://www.redbushtea.com/). Although 
not enough research could substantiate these folk remedies, more scientists became 
intrigued by the unique properties of rooibos tea.  
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1.6 Rooibos polyphenolic compounds 
1.6.1 Free radical attack 
Superoxide radical (‧O2-) is a common by-product generated from normal physiological 
functions in the body involving oxygen species, e.g. cellular respiration, activated 
polymorphonuclear lecocytes, endothelial cells, and mitochondrial electron flux (Muscoli 
et al., 2003). These highly reactive oxygen species are characterised by the loss of an 
electronic spin resulting in a molecule with an unpaired electron. Superoxide radicals can 
react with hydrogen peroxide (H2O2) to generate hydroxyl radical (‧OH-) and cause 
breakage in DNA strands, peroxidation of membrane lipids, and inactivation of cellular 
enzymes (Muscoli et al., 2003; Chen and Pan, 1996). It is clear that superoxide radicals are 
associated with the pathogenesis of several diseases, such as endothelial cell damage and 
increased microvascular permeability, promoting the inflammatory process, autocatalytic 
destruction of neurotransmitters and adrenalin and noradrenalin hormones, inactivation of 
nitric oxide important to the capacity of blood vessels to vasodilate (Muscoli et al., 2003). 
By reaction with nitric oxide the superoxide radical becomes a potent cytotoxic and 
pro-inflammatory molecule, peroxynitrite. Some clinical manifestations of explicit 
production of superoxide radicals include ischemia and reperfusion, organ transplantation, 
shock and inflammation, neurodegeneration such as Alzheimer’s disease.  
 
Solar ultraviolet (UV) radiation exposure, for example, is one of the external contributing 
factors that also cause physiological increase in production of superoxide radicals. The 
superoxides result from the interaction of UV radiation with proteins, lipids, and DNA and 
results in physiological changes such as sunburn cell formation, basal and squamous cell 
carcinomas, melanomas, cataracts, photo-aging of the skin, and immune suppression. Free 
radical attack on nuclear and mitochondrial DNA is believed to be a major contributing 
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factor to aging (Juliet et al., 2005)  
The body contains several enzymatic and non-enzymatic superoxide detoxifying agents 
(e.g. superoxide dismutase, glutathione peroxidase, catalase, thioredoxin reductase, 
tocopherol, glutathione, and ascorbic acid) to combat the various physiological stressors 
(Afaq et al., 2005). However, these natural antioxidants may be depleted and the body is 
thus put under pro-oxidant/antioxidant disequilibrium called “oxidative stress”. In order to 
restore homeostasis, antioxidants especially of botanical source have gained considerable 
attention as they are present in common foods and beverages.  
 
1.6.2 Rooibos antioxidants 
The full benefits of teas come from the combination of all the antioxidants rather than from 
just one substance (Erickson, 2003). Both flavonoids and phenolic acids in rooibos tea are 
powerful antioxidants. Flavonoids are a group of polyphenolic compounds with a flavan 
nucleus. More than 4000 flavonoids have been identified to date. In plants, they afford 
protection against UV radiation, pathogens, and herbivores. Most of the beneficial effects 
of flavonoids are attributed to their antioxidant and chelating abilities (Heim et al., 2002 
and Tammela et al., 2004). These polyphenolic compounds competitively consume the 
reactive oxygen species thus sparing the target molecule, and quench the chain reaction 
propagating free radical oxidation (Afaq et al., 2005). They act by donating a hydrogen (H+) 
atom from their hydroxyl functional groups to the reactive oxygen species. As the 
polyphenols are electron-rich compounds that contain several hydrolysable hydroxyl 
functional groups, the compound may stabilise itself when an electron is lost after 
hydrogen donation and thereby do not becoming radicals themselves.  
 
Flavonoids have been scientifically reviewed for their biological properties, apart from 
being potent antioxidants they also demonstrate to have, among others, hepatoprotective, 
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antithrombotic, antibacterial, antiviral, antitumourogenic, exhibit immunostimulant 
activities and can interact with protein phosphorylation (Bonina et al., 1996). Flavonoid 
antioxidants identified in rooibos include aspalathin, nothofagin, quercetin, isoquercetin, 
orientin, iso-orientin, rutin, luteolin, vitexin, and chrysoeriol (Bonina et al., 1996 and 
Joubert et al., 2004). Of the flavonoids identified, aspalathin, rutin and orientin occur in the 
largest quantities followed by iso-orientin and isoquercetin (Erickson, 2003 and Bramati et 
al., 2002). Joubert et al. (2004) evaluated the radical scavenging capacity of rooibos 
flavonoids and tannins, as well as the aqueous extracts and crude phenolic fractions of 
unfermented and fermented rooibos. By using 2,2-diphenyl-1-picrylhydrazyl (DPPH‧) and 
a superoxide radical (‧O2-) they found that quercetin is a stronger antioxidant than orientin, 
followed by luteolin then aspalathin against the DPPH radical. Quercetin and aspalathin 
are equally powerful as antioxidant against the superoxide anion (‧O2-).  
 
Phenolic acids found in rooibos also demonstrate antioxidant activity (Erickson, 2003). 
They are substances commonly found in fruit, vegetables and whole grains. The phenolic 
acids identified in decreasing order of activity against the DPPH radical include caffeic 
acid, protocatehuic acid, syringic acid, ferulic acid, vanillic acid, ρ-hydroxybenzoic acid, 
and ρ-coumaric acid. Caffeic acid has been found to be equally active against the DPPH 
radical compared to quercetin, aspalathin, and iso-quercetin (Joubert, 1996). 
 
In relation to being a free radical scavenger the various flavonoids contained in rooibos 
have been intensively studied as they are common phenolic compounds found in a variety 
of fruits and vegetables. The various physiological activities may be associated with 
stabilizing the reactive oxygen species halting the series of alterations in various cellular, 
biochemical and molecular changes that ultimately lead to cancer formation. 
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Quercetin and luteolin have been shown to induce apoptosis in cancer cells (Lee et al., 
2002) and may inhibit in vitro proliferation of thyroid and colon cancer cells. Quercetin 
may inhibit the effect on cyclooxygenase-2 (COX-2) expression in colonic cancer cells 
which may contribute to the prevention of colonic cancer. Both quercetin and luteolin 
(Figure 1.4) halt the formation of lipid peroxides. Quercetin also has antispasmodic 
properties that may help in infant colic (Erickson, 2003).  
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Figure 1.4: The chemical structures of quercetin (I) and luteolin (II).  
 
Orientin (Figure 1.5) has been found to reduce the number of cancer-associated cellular 
changes in blood after exposure to radiation by arresting lipid peroxidation in the liver and 
reducing damage to the bone marrow and gastrointestinal tract (Erickson, 2003).  
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Figure 1.5: The isomeric forms of orientin (Koeppen and Roux, 1965a) 
 
Rutin (Figure 1.6) maintains the strength and integrity of capillary walls and has been used 
to treat haemorhoids, varicose veins, and lower leg oedema associated with venous 
insufficiency and venous hypertension (Erickson, 2003).  
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Figure 1.6: The chemical structure of rutin.  
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Aspalathin, C21H24O11, is the major flavonoid constituent of rooibos and hence is the focus 
of this study. It is an amorphous compound and, like other rooibos constituents quercetin, 
orientin and vitexin, it is a C-glycosylflavonoid and has been characterised as 
3’-C-β-D-glucopyranosyl-3,4,2’,4’,6’-pentahydroxydihydrochalcone (Koeppen and Roux, 
1965b). The compound constitutes at least 20 % of the ethanol/acetone soluble material of 
the dried green leaves, thus considered as the major monomeric flavonoid present 
(Koeppen, 1963). This novel compound is the first known example of a naturally occurring 
C-glycosyldihydrochalcone and is found exclusively in Aspalathus linearis (Koeppen and 
Roux, 1965b and Koeppen, 1970). It can exist in two isomeric forms (Figure 1.7) which 
are readily interconvertable, and yields clusters of fine, colourless needles on 
crystallisation from acetone-ethyl acetate (Koeppen, 1970). Aspalathin is readily soluble in 
water and other polar solvents but is insoluble in non-polar media. Alkali fusion with dry 
potassium hydroxide (KOH) results in degradation of the compound to phloroglucinol and 
protocatechuic acid. However, it remains intact (no liberation of the sugar moiety) when 
refluxed with aqueous 2N hydrochloric acid (HCl) for 24 hours (Koeppen and Roux, 1966). 
This suggests that the compound may withstand gastric conditions after oral 
administration.  
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Figure 1.7: The isomeric forms of aspalathin (Koeppen and Roux, 1965b). 
 
Under the normal process of rooibos tea manufacturing less than 7 % of the aspalathin 
originally present in the unfermented tea remains after the fermentation process (Von 
Gadow et al., 1997).  Koeppen and Roux (1966) found aspalathin undergoes cyclisation 
during oxidation to form the flavanones 2,3-dihydro-iso-orientin and 2,3-dihydro-orientin 
in the presence of oxygen and sunlight, and with prolonged exposure to sunlight the 
flavanones converted to unknown brown products. The dihydrochalcones are more 
effective as antioxidants than their corresponding flavanones, which may explain the 
decrease in hydrogen-donating ability of the rooibos tea after fermentation (Von Gadow et 
al., 1997). Joubert (1996) discovered that sun-drying is not necessary for the degradation 
of aspalathin, other degradation mechanisms, such as enzymatic and chemical oxidation 
initiated with tea comminution at which time exposure to oxygen and cell damage occurs 
in the leaves may cause degradation of aspalathin in the absence of sunlight.  
 
1.6.3 Total polyphenolic content 
The traditional processing of rooibos tea entails fermentation of the harvested green leaves 
and stems producing tea that is reddish in colour with its characteristic sweet aroma. 
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During the process of fermentation, oxidation of the flavonoid contents takes place 
resulting in the loss of flavonoid antioxidants. A 150 to 200 ml serving of fermented 
rooibos tea can have up to 60 to 80 mg of total polyphenolics; a serving of 150 ml of 
fermented rooibos tea made with 2.5 g of tea leaves contain about 3 mg of aspalathin 
(Erickson, 2003). The phenolic composition of a tea extract is greatly influenced by 
fermentation, a reaction that takes place during the processing of the tea (Von Gadow et al., 
1997). Thus by eliminating the fermentation process of the tea after harvest may prevent 
loss of the flavonoids.  
 
1.6.4 Total antioxidant capacity  
The capacity of flavonoids, tannins, and phenolic fractions of fermented and unfermented 
rooibos aqueous extracts to scavenge the DPPH and superoxide anion (O2-) radicals were 
found, in decreasing order: (i) against the DPPH radical: quercetin ≥ proanthocyanidin B3 
≥ orientin ≥ luteolin ≥ aspalathin ≈ isoquercetrin > iso-orientin catechin > rutin >> vitexin 
≥ chrysoeriol; and (ii) against O2-: quercetin ≈ aspalathin > orientin ≥ catechin ≥ rutin ≥ 
isoquercetrin > iso-orientin > luteolin > chrysoeriol > vitexin (Joubert et al., 2004). 
Furthermore, Joubert et al. (2004) found that the ethyl/acetate solubles of the aqueous 
extract of unfermented rooibos and the crude aspalathin fraction exhibit the greatest 
anti-radical capacity. Marnewick et al. (2004) estimated that the total phenolic (TP) content 
of green tea as ethanol/acetone (E/A) soluble fractions was similar to that of unprocessed 
rooibos tea, and the flavonol/flavone content of the processed and unprocessed rooibos E/A 
fractions were significantly (P < 0.001) higher than that of the green tea and honeybush tea 
fractions investigated. Furthermore, when comparing green tea, unprocessed and processed 
rooibos and honeybush teas, and the green tea exhibited the greatest inhibition against lipid 
peroxidation (99%) followed by unprocessed rooibos tea (91%), processed rooibos tea 
(65%), unprocessed honeybush tea (63%), and processed honeybush tea had the least 
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protective effects (13%). 
 
1.7 Biological activities of rooibos tea  
Extracts of fermented and unfermented rooibos have been tested for various biological 
activities in the recent years. Sasaki et al. (1993) showed that fermented rooibos tea 
reduced cancer associated changes in animal cells induced by benzo(a)pyrene mutagen and 
mitomycin C mutagens both in vitro and in vivo and exhibited greater activity than green 
tea. Marnewick et al. (2000) investigated the antimutagenic properties of rooibos tea using 
the Salmonella typhimurium antimutagenicity assay. Both aqueous extracts of fermented 
and unfermented rooibos teas exhibited antimutagenic activity against 
2-acetylaminofluorene (2-AAF) and aflatoxin B1 (AFB1)-induced mutagenesis of tester 
strains TA 98 and TA 100 in the presence of metabolic activation. Oral administration of 
fermented and unfermented rooibos teas to male Fischer rats showed reduced activation of 
AFB1 in the microsomal fractions of livers of the rats (Marnewick et al., 2004). 
Furthermore, topical application of ethanol/acetone (E/A) fractions of fermented and 
unfermented rooibos tea on IRC mouse skin prior to the tumour promoter, 12-O-tetra 
decanoylphorbol-13-acetate, also showed inhibition of skin tumour formation (Marnewick 
et al., 2004). Kunishiro et al. (2001) examined the immune response of female BALN/c 
rats and Wister/ST rats fed with aqueous extracts of rooibos tea and found that the tea 
facilitated (both in vivo and in vitro) the antigen-specific antibody production through 
selective augmentation of interleukin 2 generation, and suggests that the intake of rooibos 
tea may support in the prophylaxis of diseases involving severe defect in Th (helper T cell) 
1 immune response, such as cancer, allergy, AIDS, and other infections (Kunishiro et al., 
2001). Free radical production can be proportional to the amount of oxygen consumption. 
Neuronal cells may generate much higher free radicals than other cells (Juliet et al., 2005). 
Increases in lipid peroxides in the brain results in damage of neuronal cells and contribute 
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to age-related diseases (Inanami et al., 1995). By measuring the amount of thiobarbituric 
acid reactive substances (TBARS) Inanami et al. (1995) showed protection of rooibos tea 
against several regions of the brain against lipid peroxidation in rats fed with rooibos tea. 
Ulicna et al. (2003) investigated the hepatoprotective properties of rooibos tea. Using a rat 
model where liver injury is induced by carbon tetrachloride (CCl4), rooibos tea showed 
histological regression of steatosis and cirrhosis in the liver tissue with a significant 
inhibition of the increase of liver tissue concentrations of malondialdehyde, 
triacylglycerols and cholesterol. The increase in plasma activities of aminotransferases 
(ALT, AST), alkaline phosphatase and bilirubin concentrations were also significantly 
suppressed. 
 
1.8  Aims of the study 
Over the past few years following the publication of A. Theron’s discovery on the wonders 
of rooibos tea with emphasis on the antioxidant properties of rooibos, the global sales of 
rooibos tea has increased from 750 tons in 1993 to more than 3 500 tons in 2001 (Joubert 
et al., 2004). Many studies, including animal studies, have proven that rooibos tea is 
biologically active and beneficial to the body. In relation to rooibos tea’s powerful radical 
scavenging ability, anti-ageing and UV protective properties against photo-damage of the 
skin associated with skin cancer formation, have become the two additional selling points 
of rooibos. Rooibos is no longer used only as beverage, the traditional way of benefiting 
from rooibos. Since the skin is the largest, most accessible organ of the body that is the 
most exposed area to environmental oxidative stress (Mavon et al., 2004), incorporation of 
rooibos extracts in topical cosmetic formulations has become a trend in cosmaceuticals to 
directly target the site of action to fight UV radiation damage and photo-ageing.  
 
Thus, the aim of this study was to investigate the absorption of aspalathin in rooibos tea via 
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the topical and oral routes of administration by conducting in vitro percutaneous and in 
vitro intestinal epithelial permeation experiments. Aqueous extracts of the unfermented 
(green) rooibos and pure aspalathin solution were used. Detection of aspalathin served as 
the marker of transport. The specific objectives of this study were to:  
a. Assess the percutaneous permeation of aspalathin. 
b. Quantify the amount of aspalathin permeable across the skin. 
c. Evaluate the distribution of aspalathin across the stratified layers of the skin. 
d. Assess the percutaneous permeation of skin care product containing rooibos extract.  
e. Assess the permeation of aspalathin across intestinal epithelium. 
f. Quantify the permeable aspalathin across the intestinal epithelium. 
g. Evaluate the permeability of aspalathin in a Pheroid technology formulation across the 
intestinal epithelium. 
h. Compare aspalathin permeation in the green rooibos aqueous extract and in the pure 
aspalathin solution. 
 
In the in vitro percutaneous permeation study female human abdominal skin was used and 
the permeation experiments were conducted at the Department of Pharmaceutics, 
North-West University (Potchefstroom campus). The in vitro intestinal epithelial transport 
study involved Caco-2 cell monolayers and the transport experiments were performed at 
the School of Pharmacy, Tshwane University of Technology, Pretoria. 
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CHAPTER 2: IN VITRO PERCUTANEOUS PERMEATION OF ASPALATHIN 
 
2.1 Overview of the human skin  
Early records of Babylonian and Egyptian medicine indicate that topical delivery has been 
used as a route of medicinal delivery (Hadgraft and Lane, 2005) through ointments, salves 
and pomades (Hadgraft and Somers, 1965). Drug administration via skin is mainly 
categorised into two approaches: (1) topical delivery, for local therapeutic effects, e.g. on 
diseased skin; and (2) transdermal delivery for systemic therapeutic effects. In either case, 
drug molecules need to be taken up by the skin. The term skin uptake is commonly used to 
describe the fate of drugs upon their entry into the skin. It is a broad definition that 
encompasses retention, permeation, metabolism, degradation and binding to skin 
components, various activities which a drug can undergo upon partitioning into the skin. In 
case of topical delivery, the objective is to have optimal drug residence in the skin layers 
i.e. skin retention. Whereas in the case of transdermal delivery, an optimal net transport 
across the skin (skin permeation) becomes an important criterion in determining the drug 
efficacy (Behl et al., 1990) 
 
The ability of drugs to permeate the complex, multilayered, heterogenous skin (i.e. skin 
permeability) varies as a function of individuals, body site, race, gender, age, overall skin 
condition and the state of the skin, that is, diseased or normal (Behl et al., 1990). Flynn 
(1979) reports that the permeability of skin of the same body site of apparently healthy 
individuals can differ as much as ten-fold. For example, premature babies have 
exceptionally permeable skin as opposed to senile skin which is dry, irritable and poorly 
vascular. The stratum corneum of Caucasian and black skin have essentially equal 
thickness but the latter contains more cell layers and is more dense. Therefore, the black 
skin is less permeable than white skin (Flynn, 1979). 
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Drug delivery via the skin offers several advantages over conventional routes. It avoids the 
first-pass metabolism by the liver and enzymatic degradation in the gastrointestinal tract. It 
is a non-invasive method of drug delivery with no trauma or risk of infection that has the 
potential for sustained and controlled drug release, and may improve patient compliance 
because its user-friendliness (Denete et al., 2004). However, because the skin is a complex 
organ that serves to protect the body against harmful invasions from the external 
environment, the transdermal drug delivery systems are faced with barriers and difficulties 
that will be discussed further in the following section.  
 
2.1.1 Structure of the skin 
The skin is the largest and most easily accessible organ of the body (Thomas and Finnin, 
2004). It is a complex organ that serves to protect the underlying tissues against external 
physical, chemical, immunological and pathogenic intrusion as well as ultraviolet (UV) 
radiation and free radical attacks, while retaining moisture and providing thermal 
regulation (Ho, 2004). It is the major thermoregulatory organ and contains sensory organs 
for sensing pressure, pain and temperature. The skin also functions as an endocrine gland 
synthesising vitamin D by peripheral conversion of prohormones. In addition, it plays a 
significant role in reproduction in presenting secondary sexual characteristics and 
pheromone production (Flynn, 1979). 
 
The skin can be divided into three primary regions: the epidermis, the dermis, and the 
hypodermis (Figure 2.1).  
  21 
 
Figure 2.1: Schematic diagram of cross-section of human skin 
(http://rds.yahoo.com/_ylt=A9G_RtvPXEdE8BcB6pujzbkF;_ylu=X3oDMTA4NDgyNWN
0BHNlYwNwcm9m/SIG=12ve841bm/EXP=1145613903/**http://www.anti-aging-skin-ca
re.com/forever-young-how-it-works-diagram.html). 
 
2.1.1.1 Epidermis  
The stratified epidermis is the outermost layer of the skin which is in contact with the 
environment. It can be divided broadly into two layers: the stratum corneum and the viable 
epidermis. The viable epidermis consists of cells that can be further categorised into three 
layers that are in continuous differentiation moving outwards to the body surface; the 
stratum basale, the stratum spinosum, and the stratum granulosum. The epidermis is 
between 75 to 200 µm thick in most regions and 400 to 600 µm in the palms and soles (Ho, 
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2004). It is avascular and the cells in this layer are continually shed to the surface of the 
skin and replaced from the basal layer. The epidermis has a papillose interface with the 
dermis such that it projects into the dermis like tiny finger bulges. Epidermal cells also 
extend to subcutaneous regions to form follicular sheaths of hair follicles, which is an 
epidermal structure. This is important as in the events of skin injury regeneration of a new 
surface without scarring is possible as long as the tissue damage does not extend to the 
bulb of the hair (Flynn, 1979).  
 
Since the stratum corneum has been recognised as the rate controlling membrane in 
transdermal delivery of drugs and chemicals (Behl, 1990 and Hadgraft and Lane, 2005), 
only this layer of the epidermis will be discussed in further detail. 
 
Stratum corneum 
The stratum corneum is the outermost layer of epidermis as well as the primary permeation 
barrier of most drugs and chemicals. The stratum corneum consists of 20 to 40 % water,  
20 % lipid, and 40 % keratinised protein (Ho, 2004). This epidermal layer is roughly 10 to 
20 µm (15 – 20 cell layers) thick (Ho, 2004 and Hadgraft, 2004) with individual 
corneocytes being, on average, approximately 0.3 µm in thickness covering 1 100 to      
1 200 µm2 of the skin (Cevc, 2004). Groups of up to twelve corneocyte columns in the 
stratum corneum form clusters that characterize the basic skin permeation resistance unit. 
The junctions between corneocyte clusters correspond to the microscopically detectable 
surface corrugations that are considered as a “hot spot” for transdermal delivery (Cevc, 
2004). More than 90 % of all cells in the stratum corneum are terminally differentiated 
(dead) keratinised cells (keratinocytes or corneocytes) tightly packed and connected to one 
another in a planar array by desmosomes (Cevc, 2004). Filling the intercellular spaces are 
lipid lamellae that tightly seals this region forming a continuous and extremely tortuous 
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intercellular network (Cevc, 2004 and Ho, 2004). This organisation results in the 
diffusional path length being much longer than the simple thickness of the stratum 
corneum through which substances have to traverse and has been estimated as long as  
500 µm (Hadgraft, 2004). The compactness of the corneocytes and the densely packed 
lipid multi-layers is often likened to a brick-and-mortar wall. The aqueous protein phase in 
the corneocytes is modelled to the bricks and the intercellular lipid phase is modelled as a 
continuous mortar (Ho, 2004 and Hadgraft and Lane, 2005) acting predominantly as a 
lipophilic barrier (Hadgraft and Lane 2005), resulting in the already resistant transport 
pathway even less permeable (Behl, 1990).  
 
The stratum corneum is under continuous formation as fully differentiated cells from 
beneath replace those that are worn off the surface. The total turnover rate of the stratum 
corneum is approximated two weeks in normal adults (Flynn, 1979). 
 
2.1.1.2 Dermis and hypodermis 
The dermis is a highly vascularised skin layer that embeds the microcirculations that 
supply the entire skin. Networks of lymphatic and sensory nerves for pressure, temperature 
and pain are also found in the dermis. Chemicals applied onto the skin must permeate 
through the epidermis to reach the underlying dermis for uptake into the systemic 
circulation. The dermis contains moderately dense connective tissue composed of collagen 
and elastic fibres. Its thickness varies from 1 to 4 mm depending on the location in the 
body (Ho, 2004).  
 
Skin appendages, the hair follicles and the sweat glands, break the continuity of the 
epidermal and dermal layers throughout most of the surface of the body. On average, there 
are approximately 40 to 100 hair follicles and 210 to 220 sweat ducts perforating per 
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square centimeter of skin, occupying about 0.1 % of the total body surface area (Ho, 2004). 
The hair follicles root in the dermis where the bases are well vascularised and extend 
through the epidermis to the skin surface. Sebaceous glands co-exist with hair follicles 
secreting sebum into the region between the hair and the sheath. The sweat glands consist 
of tubes extending from the dermis, where the tube is coiled and vascularised to the skin 
surface where sweat is excreted to provide thermal regulation (Ho, 2004).  
 
2.1.2 Routes of penetration through the skin 
Three primary transport pathways through skin have been described: (1) intercellular 
diffusion through the lipid lamellae; (2) transcellular diffusion through both the 
corneocytes and the lipid lamellae; and (3) diffusion through skin appendages (hair 
follicles and sweat ducts). Figure 2.2 illustrates the proposed pathways. 
 
 
Figure 2.2: Skin permeation routes: (1) intercellular diffusion through the lipid lamellae; 
(2) transcellular diffusion through both the corneocytes and the lipid lamellae; and (3) 
diffusion through skin appendages (hair follicles and sweat ducts) (Ho, 2004). 
 
Intercellular diffusion through the lipid lamellae is considered to be the predominant route 
of transport (Ho, 2004 and Hadgraft, 2004). The intercellular spaces consist of structured 
lipids and diffusing molecules need to cross a variety of lipophilic and hydrophilic 
domains of the skin to reach the underlying cell layers (Hadgraft, 2004).  
 
  25 
Figure 2.3 is a schematic diagram of the principal steps of penetration. In brief, drug 
molecules applied onto the skin undergo passive diffusion within their carrier system 
(vehicle) to the surface of the skin, followed by partitioning into the stratum corneum. 
After entering the lipophilic stratum corneum and the sweat glands an inward diffusion of 
the drug takes place and continues into the hydrophilic viable epidermis and dermis (local 
tissue). This creates a concentration gradient across the skin between the surface of the skin 
and the microcirculation imbedded in the dermal layer. Once the drug reaches the general 
circulation it is distributed very rapidly; and due to reasonable rates of systemic 
metabolism and elimination, generally no appreciable systemic build-up occurs. This 
phenomenon, maintaining a near-zero concentration of the drug on the plane of the 
capillaries (dermal layer) is called sink condition and is necessary for the driving force of 
the diffusion process (Flynn, 1979).  
 
 
Figure 2.3: Schematic diagram of the principal steps of permeation (modified from Zatz, 
1993). 
 
Key factors that control molecular permeation through the stratum corneum of the skin, in 
Vehicle 
Stratum corneum 
and sweat glands 
Viable epidermis and dermis 
Blood Hypodermis 
Hydrophilic 
porous shunt 
pathways 
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decreasing sequence of importance, are molecular lipophilicity, size, and the ability to 
interact with other molecules, e.g. via hydrogen bond formation (Cevc, 2004). 
Consequently, molecules larger than a few hundred Dalton and/or highly polar compounds 
that cannot efficiently pass through the skin by simple diffusion may alternatively traverse 
the skin via the hydrophilic porous pathways, i.e. the transport shunts (Cevc, 2004).  
 
2.1.3 Physicochemical parameters influencing transdermal drug delivery 
Absorption of drugs and chemicals into or across the skin is influenced by a number of 
factors: physicochemical properties of the permeant, condition and type of skin, other 
chemicals (e.g. vehicles or enhancers) present with the permeant, and external conditions 
(e.g. temperature, humidity, and occlusion) (Smith, 1990). Diffusion through the skin can 
be described by Fick’s law of diffusion. The most basic diffusion equation is Fick’s first 
law: 
 
J = KD(capp – crec)/h                                                  (1) 
 
Where J = steady state flux per unit area (µg/h/cm2), 
     K  = partition coefficient of the permeant between the applied formulation and skin, 
     D = diffusion coefficient of permeant, 
     h = diffusional pathlength, 
    capp = applied concentration of the permeant in the vehicle, 
    crec = concentration of the permeant in the receptor phase. 
 
The diffusivity and the concentration gradient of the drug within the skin influence flux 
across the skin. The concentration gradient itself is influenced by the ability of the drug to 
partition into the skin and its ability to partition out of the skin into the underlying tissues. 
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The octanol/water partition coefficient Kow, as expressed by log P (log Kow), can be used to 
predict this partitioning behaviour between an aqueous vehicle and skin (Thomas and 
Finnin, 2004). In most circumstances crec << capp as a result of sink condition and thus Eq. 
(1) is often simplified to:  
 
J = kpcapp                                                          (2) 
 
where kp = (KD/h) is the permeability coefficient. This parameter (from an aqueous donor 
phase) may be estimated by an empirical relationship described by Cronin et al. (1999) 
who deduced a correlation between the permeability coefficient kp, octanol/water partition 
coefficient (Kow), and molecular weight (MW) of a permeant (Cevc, 2004): 
 
log kp ≡ log P – log (D/dsc) 
  = 0.77 log Kow – 0.013 MW – 2.33  
                                                             [n = 107] 
                                                                  (3) 
 
This correlation produced higher significance (r2 = 0.86) and similar results to the previous, 
statistically inferior relationship of Potts and Guy (1992): log kp = 0.71 log Kow – 
0.0061MW – 6.3, n = 93, r2 = 0.67. Thus, using Eq. (3), transdermal diffusion of large 
molecules will fall below 1 µg/h/cm2 when either MW > 328 for log Kow = 1 or else when 
permeant hydrophilicity exceeds log P = - 1.34 for MW = 50, assuming 1 wt.% 
drug-in-vehicle solubility limit (Cevc, 2004). 
 
The maximum flux of a molecule is achieved when the applied concentration capp is equal 
to the solubility of the permeant in the vehicle. From the equations it can be seen that the 
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important physicochemical parameters are the partition coefficient, diffusion coefficient, 
and solubility; and increasing MW will decrease the rate of diffusion. Molecules with low   
log P exhibit low permeability because little partitioning into the stratum corneum occurs. 
On the other hand, molecules with high log P values also confer low permeability due to 
their inability to partition out of the stratum corneum (Thomas and Finnin, 2004). In 
general, molecules must have good solubility in both oils and water and with a log P ~ 1 – 
3 for maximum permeation (Hadgraft, 2004).  
 
Many permeants are weak acids or weak bases and therefore, their degree of ionization 
will influence their solubility in the applied phase as well as the diffusion through the skin. 
If a permeant is ionisable in quantities dependent on pH, the transport of the ionised 
species will occur less rapidly than transport of the unionised species due to interactions 
between the polar head groups of the intercellular lipids with hydrogen-bond-forming 
functional groups in the permeant structure (Thomas and Finnin, 2004). As a general rule, 
the number of hydrogen bonding groups in the permeant should not exceed two (Thomas 
and Finnin, 2004). Higher flux is obtained by maintaining the pH in the vehicle such that 
the permeant is unionised. However, pH values outside the physiological range of pH 4 – 7 
may also change properties of the skin that could affect solubility, partitioning or binding, 
resulting in changes in transdermal penetration (Smith, 1990 and Hadgraft, 2004).  
 
2.2 Materials and methods 
2.2.1 Materials 
The powdered extracts of green (unfermented) rooibos (GRE) obtained by aqueous 
extraction (EURO Ingredients) was provided by Dr. E. Joubert. The aspalathin pure 
compound was obtained from PROMEC (Tygerberg, South Africa). Two commercial skin 
care products (cream) containing the green rooibos extracts (quantity unspecified) were 
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obtained from local pharmacies. HPLC grade acetonitrile (CH3CN) and 0.1 % acetic acid 
(CH3COOH) were obtained from BHD Laboratory Supplies (Poole, UK). Potassium 
dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate dihydrate 
(Na2HPO4·2H2O), and sodium chloride (NaCl) were supplied by Merck (Midrand, South 
Africa) (ISO 9001 certified). n-Octanol (98 %) was obtained from Acros Organics 
(Edenvale, South Africa). Double distilled water was prepared by a Milli-Q water 
purification system (Millipore, Milford, USA), which was used throughout the study.  
 
2.2.2 High performance liquid chromatography (HPLC) method for the analysis of 
aspalathin 
2.2.2.1 Apparatus 
All analyses were carried out using a HPLC system (Agilent 1100 series, Palo Alto, CA, 
USA) equipped with a diode array UV detector, gradient pump, autosampler injection 
device, and Chemstation Rev. A.08.03 data acquisition and analysis software. A Luna 
C18-2 column (150 x 4.6 mm, 5 µm particle size) from Phenomenex® (Torrance, CA, USA) 
was used.  
 
2.2.2.2 Chromatographic conditions 
All analyses were performed at a flow rate of 1.0 ml/min and the mobile phase consisted of 
a mixture of HPLC grade acetonitrile (CH3CN) and 0.1 % acetic acid (CH3COOH) in 
HPLC grade water, buffered at pH 7.4 with 0.02 M potassium dihydrogen phosphate 
(KH2PO4). The column temperature was held constant at 25 °C and the effluent was 
monitored at a wavelength of 287 nm. The retention time for aspalathin was approximately 
7.5 ± 0.3 minutes. The injection volume for all the samples was 50 µl. The total time of 
detection was 20 minutes for all samples and separation was performed by solvent gradient 
elution as shown in Table 2.1. 
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Table 2.1: Gradient elution employed for reverse-phase HPLC separation of aspalathin.  
Time (min) Solvent composition (% acetonitrile) 
0 5.0 
5:00 25.0 
12:00 25.0 
12:50 80.0 
16:00 80.0 
16:20 5.0 
20:00 5.0 
 
2.2.2.3 Preparation of stock solution 
A stock solution with a concentration of 730 µg/ml was prepared by dissolving 3.65 mg 
aspalathin in 5 ml of HPLC grade water. The stock solution was stored in the dark at   
-20 °C and was stable for at least 3 months.  
 
2.2.2.4 Validation of HPLC procedure 
The method was validated according to ICH guidelines (ICH, 2005). 
2.2.2.4.1 Linearity 
A calibration curve for aspalathin was established by preparing standard solutions from the 
stock solution by performing a serial dilution consisting of the following concentrations: 
0.6, 2.9, 5.8, 14.6, 29.2, 73.0, 146.0, 365.0, and 730.0 µg/ml. Linear regression analysis 
from the plot of peak area versus concentration of the analyte was performed and the 
obtained calibration equation was y = 111.69x + 0.5196 where the correlation coefficient 
(R2) was found to be better than 0.999. 
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2.2.2.4.2 Accuracy and precision 
Accuracy was determined as the relative deviation of the obtained value from the nominal 
value and was calculated as follows:  
 
Accuracy (%) = analysed conc. X 100 
added conc.     1 
 
The precision is the determination of the closeness of measurements after multiple sample 
preparations of the same homogenous sample mixture i.e. the relative standard deviation 
(% RSD) of the analysed concentration. Accuracy and precision were determined by HPLC 
analysis of three different concentrations (11.53, 115.3, and 345.9 µg/ml) each in triplicate 
(n = 9) on the same day. The results are presented in Table 2.2. The values obtained for all 
three concentration levels were lower than 1.0 % and therefore, the method could be 
considered as accurate and precise.  
.  
Table 2.2: Quantification of accuracy and precision of aspalathin recovery from three 
concentrations. 
Added conc. 
(µg/ml) 
Analysed conc. 
(µg/ml) (mean ± SD) 
(n=3) 
Accuracy (%) 
(n=3) 
Precision  
(%RSD) 
(n=3) 
11.5 11.63 ± 0.042 100.86 0.362 
115.3 115.44 ± 0.142 100.12 0.123 
345.9 346.73 ± 1.95 100.24 0.563 
SD = standard deviation. 
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2.2.2.4.3 Sensitivity 
The sensitivity of the analytical HPLC method for aspalathin was assessed by determining 
the lowest limit of quantification, and the limit of detection. The sensitivity of a method 
can be improved by increasing the sample volume.  
 
The limit of quantification (defined as the lowest concentration of an analyte in a sample 
that can be determined with acceptable precision and accuracy) is a parameter of 
quantitative assays for low levels of compounds in sample matrices. It is used in particular 
for the determination of impurities and/or degradation products. The quantification limits 
for aspalathin was 0.584 µg/ml. 
 
The limit of detection is the lowest concentration of analyte in a sample that can be 
detected, but not necessarily quantified. The detection limit for aspalathin was 0.06 µg/ml.  
 
2.2.2.4.4 Selectivity 
Selectivity is the capacity of an analytical method to analyse a component in the presence 
of other components such as degradation products and biological material. Figure 2.4a 
shows a chromatogram of an aspalathin standard with a single, well separated peak at a 
retention time of 7.66 min. An aspalathin peak amongst other unidentified flavonoid 
compounds was elucidated at 7.77 min in the GRE (Figure 2.4b). Figure 2.4c and Figure 
2.4d show HPLC chromatograms of a blank skin tissue (epidermis and dermis) sample and 
a blank tape strip (stratum corneum) sample. Samples of blank skin tissue and blank tape 
strip were obtained using the method described in section 2.2.6.3 and 1ml of phosphate 
buffer system (PBS) (pH 5.5) was used on the donor compartment in place of the test 
formulations. No peaks at the retention time of aspalathin were elucidated indicating that 
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the skin tissue and tape strip samples had no interference with aspalathin detection. 
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Figure 2.4a: HPLC chromatogram and UV spectrum of aspalathin (7.05 µg/ml), Rt = 
7.658 min. 
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Figure 2.4b: HPLC chromatogram and UV spectrum of green rooibos extracts (5 µg/ml) 
aspalathin Rt = 7.823. 
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Figure 2.4c: HPLC chromatogram of skin tissue. 
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Figure 2.4d: HPLC chromatogram of skin surface sample. 
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2.2.3 Determination of stability of aspalathin in transport medium 
Phosphate buffer systems (PBS) of mixtures of 0.2 M potassium dihydrogen phosphate 
(KH2PO4) solution (27.2 mg/ml) and disodium hydrogen phosphate dihydrate 
(Na2HPO4·2H2O) solution (35.6 mg/ml) were prepared according to British Pharmacopoeia 
(1993) and buffered to pH 5.0, pH 6.0, and pH 7.0, respectively. Samples of 1.4 µg/ml of 
aspalathin were prepared in PBS of the respective pH values and left on an autosampler 
tray at room temperature 25 °C for analysis by HPLC at hourly intervals for 14 hours. The 
percentage of aspalathin from the initial concentration was plotted as a function of time 
and is shown in Figure 2.7a, depicting the percentage loss of aspalathin over time. 
 
Another stability test was performed to determine at which pH value of the PBS the 
permeation experiment should be carried out. PBS buffered at pH 5.0 and pH 5.5 were 
prepared as mentioned above. Samples of 1.4 µg/ml of aspalathin were prepared in PBS of 
the respective pH values and left on an autosampler tray at room temperature 25 °C for 
analysis by HPLC for 9 hours. Figures 2.7b is a plot of the percentage of aspalathin from 
the initial concentration versus time. 
 
In addition, samples of GRE and aspalathin solution test formulations were left in the 
water bath (37 °C) for the duration of the permeation experiment and the concentration of 
aspalathin from the two test formulations at time zero and at the end of the experiment was 
compared for monitoring the stability of aspalathin.  
 
2.2.4 Determination of octanol/water partition coefficient (Kow) 
In section 2.1.1.1 the stratum corneum of the skin was discussed and modelled to 
“brick-and-mortar”, where the structure of stratum corneum consists of a continuous lipid 
phase surrounding a large number of thin parallel polar protein “plates”. When this 
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structure is intact, permeation occurs either by diffusion through both the lipophilic lipid 
phase and the hydrophilic protein phases or (for lipophilic permeants) by diffusion via the 
tortuous pathway solely through the lipid phase (Smith, 1990). Permeation requires good 
solubility of the permeant in both lipophilic and hydrophilic phases. The principal use of 
partition coefficient K is in predicting relative rates of transport between two liquid phases. 
The partition coefficient of a compound between the lipid domain and protein domain of 
the stratum corneum can be related to the partition between octanol and water to allow for 
experimental validation of the two-domain concept (Rieger, 1993). Since the permeation 
experiment utilises a phosphate buffer system at pH 5.5 as the donor phase, the water phase 
in the determination of Kow was replaced with a phosphate buffer system (pH 5.5), but will 
still be referred to as octanol/water partition coefficient. The Kow of aspalathin was 
experimentally determined by pre-saturating 250 ml of phosphate buffer system and   
250 ml of n-octanol with one another in a separating funnel. Aspalathin solution of     
0.1 mg/ml was prepared by dissolving 1 mg aspalathin in 10 ml of the pre-saturated 
phosphate buffer system (pH 5.5) giving a clear solution of aspalathin (solution not 
saturated). Approximately 2 ml of the aspalathin solution (n =3) was mixed with 2 ml of 
n-octanol in a 10 ml screw-cap test tube and tumbled in a water bath at 25 °C for 24 hours. 
The mixture was then centrifuged for 30 minutes at 3000 rpm (relative centrifuge force 
(RCF) 377.33 g) and 250 µl of each phase was removed and analysed by HPLC. The 
phosphate buffer system phase was analysed as is and the n-octanol phase was diluted 1:4 
with methanol prior to analysis. The concentration of the aspalathin was calculated with 
the calibration curve established in 2.2.2.4.1 and Kow was determined by the relationship of 
the amount dissolved in each phase as follow: 
 
Kow = co / cw 
                                                                  (4) 
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Where co  = concentration in octanol phase, 
      cw = concentration in water phase. 
 
2.2.5 Determination of aspalathin in commercial products  
Approximately 2 g of each of the commercial products (n = 2) was extracted with 8 ml of: 
(i) methanol/water 50/50 v/v; and (ii) tetrahydrofuran, respectively, in a 15 ml screw-cap 
test tube and placed in a water bath at a constant temperature of 60 °C for 5 minutes. The 
dispersions were allowed to cool down after extraction, made up to 10 ml and centrifuged 
at 3000 rpm (relative centrifuge force (RCF) 377.33 g). The supernatant was analysed by 
HPLC. 
 
2.2.6 Aspalathin permeation study 
2.2.6.1 Preparation of test formulations  
In a preliminary HPLC analysis of the green rooibos aqueous extracts, approximately   
1.0 mg/ml (20 %) of aspalathin was found in 5.0 mg/ml of green rooibos aqueous extracts. 
Thus, the test formulations subject for testing were prepared as follows: 5.0 mg/ml green 
rooibos extracts and 1.0 mg/ml aspalathin solutions were prepared by dissolving 35.0 mg 
of GRE and 7.0 mg aspalathin in 7.0 ml of PBS (pH 5.5). The resulting test formulations 
contained approximately the same concentration of aspalathin.  
 
Sodium chloride (NaCl) saline solution (0.9 %) for the skin integrity test prior to the 
permeation experiment was prepared by dissolving 900 mg NaCl in 100 ml water.  
 
2.2.6.2 Preparation of skin 
Human abdominal skin was used in the permeation study. Full thickness white female 
abdominal skin was obtained from 2 individual patients who underwent cosmetic surgery 
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and kept frozen at -20 °C for no longer than 24 hours after removal. The skin was thawed 
at room temperature, washed with distilled water and dried with paper tissue. 
Split-thickness skin of approximately 400 µm in thickness, comprising of the stratum 
corneum, viable epidermis and part of the upper dermis, was dermatomed (Figure 2.5) 
using a Zimmer® electric dermatome and placed onto Whatman® filter paper. The skin 
samples prepared were wrapped and sealed in aluminium foil and kept frozen at -20 °C 
until utilised. Prior to conducting the diffusion study the frozen skin samples were thawed 
at room temperature, examined for defects, and cut into circles of approximately 15 mm in 
diameter (n = 6 from skin donor 1 and n = 6 from skin donor 2) for mounting onto the 
diffusion apparatus. Storage of skin up to 6 months at -20 °C showed no impact on skin 
integrity (Harrison et al., 1984). 
 
 
Figure 2.5: Skin dermatome obtaining split-thickness skin using a electric dermatome 
(http://www.zimmergermany.de and http://www.residentnet.com). 
 
2.2.6.3 Transport of aspalathin across skin 
Vertical Franz diffusion cells (Figure 2.6) consisting of an upper donor compartment and 
lower receptor compartment were used in the permeation study, with a receptor capacity of 
approximately 2.0 ml and a diffusional area of 1.131 cm2. A small magnetic stirring bar 
was placed in each receptor compartment to maintain stirring throughout the entire 
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experiment. The prepared skin was thawed prior to the experiment and mounted onto the 
receptor compartment with the stratum corneum facing up in the direction of the donor 
compartment. The donor compartment was then placed and fastened onto the receptor 
compartment with a metal clamp, wedging the skin between the two compartments. The 
donor and receptor compartments were then loaded with 0.9 % NaCl solution and the cells 
placed into a preheated water bath at 37 °C which results in a skin surface temperature of 
32 °C and equilibrated for approximately 30 minutes. After equilibration, the integrity of 
the skin in each cell system was assessed by measuring the transepidermal electrical 
resistance (TEER) using a Tinsley LCR Databridge (Model 6401). The reading was 
conducted at a frequency of 1 kHz with a maximum voltage of 300 mV root mean square 
in the parallel equivalent circuit mode utilising an alternating current. The experimental set 
up was according to the study of Fasano et al. (2002). Skin discs with TEER values 
between 14.0 and 25.0 kΩ were selected for use in this study. It was important for a 
comparison study to select cells with similar resistance values. The 0.9 % NaCl solution in 
the donor and receptor compartments was removed. The receptor compartments were filled 
with PBS (pH 5.5) with caution to avoid air bubbles underneath the skin. Therefore, the 
PBS was degassed in an ultrasonic bath for 15 min prior to the experiments. The donor 
compartments were loaded with 1 ml of freshly prepared GRE (n = 6) and pure aspalathin 
solutions (n = 6), respectively, and immediately covered with a cap to prevent any 
significant evaporation during the permeation experiment. The cell systems were left in the 
water bath at a constant temperature (37 °C) for 12 hours to allow permeation to take place. 
The receptor phases sampled after 12 hours of incubation were analysed by HPLC and the 
skin discs dismounted from each cell system were subjected to tape stripping. 
 
  41 
 
Figure 2.6: Vertical Franz diffusion cell consisting of an upper donor compartment 
(chamber) and bottom receptor compartment (re-drawn from http://www.permegear.com/fr 
anz.htm). 
 
2.2.6.4 Tape stripping the stratum corneum and epidermis 
An adhesive tape (3M Scotch® MagicTM Tape) was cut into pieces the size of the skin 
dismounted from each cell system and placed onto the stratum corneum of the skin. The 
tape was smoothed out on the skin to ensure even pressure and contact with the skin and 
then gently peeled off from the skin removing some cells of the stratum corneum. This 
process was repeated 14 times with each skin disc and a total of 15 tapes for each skin disc 
were obtained and placed into a vial containing approximately 2 ml of PBS (pH 5.5). The 
remaining skin (epidermis and dermis) after tape stripping was then cut into smaller pieces 
to increase surface area for extraction and put into a separate vial containing approximately 
1 ml PBS (pH 5.5). All collected samples were kept in a fridge at 4 °C overnight to allow 
extraction of aspalathin into the PBS. Samples were then filtered and withdrawn from the 
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tape strip (stratum corneum) solutions and the skin solutions and were subjected to HPLC 
analysis.  
 
2.2.6.5 Sample analysis 
The concentration of each sample was calculated from the analysed peak area using the 
calibration curve. The amount of aspalathin in each sample could be determined with the 
volume and dilution factor and were expressed as mass of aspalathin per diffusional area 
(µg/cm2). 
 
2.2.6.6 Statistical analysis 
The experiment was conducted with skin obtained from 2 different skin donors. Each 
donor skin was able to produce three replicates (n = 3) of each of the two test formulations 
resulting in a total of six replicates (n = 6) for each formulation. Data were expressed as 
means ± standard deviation (SD). Differences between mean values of the two different 
tested formulations were analysed by means of one-way analysis of variance (ANOVA). 
The difference between the two formulations was assessed and P-values < 0.05 were 
considered to be significantly different. 
 
2.3 RESULTS AND DISCUSSION 
2.3.1 Stability in transport medium 
The stability of aspalathin in PBS of pH 5.0, 6.0, and 7.0 over 14 hours is depicted in 
Figure 2.7a. The highest aspalathin degradation occurred at pH 7.0 with a loss of 
approximately 40 % over 14 hours, followed by pH 6.0, and the least at pH 5.0. Figure 
2.7b is a plot of the percentage of aspalathin from approximately 1.4 µg/ml pure aspalathin 
solution, buffered at pH 5.0 and pH 5.5 versus time. Less than 30 % of the aspalathin was 
lost in the pH 5.5 PBS. Since the physiological pH of the skin is pH 5.5 and less 
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degradation occurred at this pH range, the permeation experiment in this study was carried 
out using PBS buffered at pH 5.5. 
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Figure 2.7a: Amount of aspalathin (% of initial concentration) in 1.4 µg/ml of aspalathin 
solution, buffered at pH 5.0, 6.0, and 7.0, stored for 14 hours at room temperature (25 °C). 
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Figure 2.7b: Amount of aspalathin (% of initial concentration) in 1.4 µg/ml pure 
aspalathin solution, buffered at pH 5.0 and 5.5, at room temperature (25 °C) for 9 hours. 
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In addition, the applied concentrations of the test formulations were approximately 1.13 
mg/ml and 0.93 mg/ml of aspalathin in GRE and in pure aspalathin solutions, respectively. 
After 12 hours of incubation in water bath approximately 1.3 mg/ml and 1.0 mg/ml of 
aspalathin elucidated, respectively. This indicates that the aspalathin was stable under the 
experimental conditions. The difference in concentration between the initial and the end 
concentration may be a result of error in analysis. 
 
2.3.2 Octanol/water partition coefficient (Kow) 
For a molecule to permeate well through the skin it must have good solubility in both the 
water phase and oil phase, and exhibit a log P of ~1 – 3 for optimum partition behaviour 
(Hadgraft, 2004). However, the Kow (n = 3) of aspalathin was 0.450 and log P equals -0.347 
with a RSD of 6.6 %. Drugs displaying log P values close to 2 are generally predicted to be 
completely absorbed in humans (Artursson et al., 2001). Table 2.3 is the experimentally 
determined Kow and calculated log P value. The permeability coefficient (kp) of aspalathin 
was calculated using Eq. 3 and was 1.52 x 10-4 cm/h. 
 
log kp = 0.77 log Kow – 0.013 MW – 2.33  
  = 0.77 log 0.450 – (0.013 x 452.41) – 2.33 
  = -3.818 
kp  = 1.52 x 10-4 cm/h 
 
Due to the low log P it can be expected that the partitioning of aspalathin from the vehicle 
into the stratum corneum will be very low. Hence, it could be expected that aspalathin 
would not permeate human skin to an appreciable amount which can be seen from the low 
kp value. 
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Table 2.3: Octanol/water partition coefficient (Kow) of aspalathin and log P value. 
Mean concentration (µg/ml)         Kow        Log P   
  PBS n-Octanol   
  
  
  
AV 
SD 
% RSD 
57.9 
56.5 
56.2 
56.9 
0.907 
1.596 
27.9 
23.9 
25.1 
25.6 
2.053 
8.008 
0.482 
0.423 
0.447 
0.450 
0.030 
6.575 
-0.317 
-0.374 
-0.350 
-0.347 
0.028 
-8.191 
 
2.3.3 Determination of aspalathin in commercial products 
Cream extraction was performed with two extraction methods (i) water/methanol (1:1) and 
(ii) tetahydrofuran. Table 2.4 presents the concentration of aspalathin per gram of cream 
analysed. In cream A, both extraction methods produced aspalathin amounting to 
approximately 0.871 µg/g and 0.922 µg/g of cream, respectively, composing less than   
0.1 % of the cream. The peak areas of aspalathin elucidated by HPLC in cream B were 
diminutive and below the limit of detection, therefore, the amount of aspalathin in cream B 
was not detectable. Figure 2.8 shows the chromatogram of cream A with a small peak 
representing aspalathin elucidating at 7.48 min. 
 
Due to the negligible amount of aspalathin detected in the commercial products and limit 
of detection of aspalathin by HPLC, the permeation study on the products was considered 
not feasible and investigation of aspalathin penetration from the creams was not carried 
out. 
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Table 2.4: Amount of aspalathin extracted per gram of cream using (i) water/methanol (1:1) 
and (ii) tetrahydrofuran extraction methods (n = 2). 
Water/methanol (1:1) Tetrahydrofuran   
Cream A (µg/g) Cream B (µg/g) Cream A (µg/g) Cream B (µg/g) 
  
  
AV 
SD 
% RSD 
0.938 
0.804 
0.871 
0.095 
10.879 
n/a* 
n/a* 
n/a* 
n/a* 
n/a* 
0.728 
1.116 
0.922 
0.274 
29.757 
 n/a* 
n/a* 
n/a* 
n/a* 
n/a* 
* Amount of aspalathin was below the limit of detection (0.06 µg/ml). 
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Figure 2.8: Chromatogram of a water/methanol extract of cream A depicting aspalathin at 
7.48 min and other flavonoid compounds. 
 
2.3.4 Aspalathin permeation study 
This permeation study employed excised human skin that had been frozen for storage, thus 
the metabolic systems found in viable skin no longer function and permeation of aqueous 
soluble substances across frozen skin may be greater than that through fresh skin (Brain et 
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al., 2005). The occlusion method employed to prevent water loss from the stratum 
corneum during the experiment may increase fluidity of the intercellular lipid domains 
within the stratum corneum and cause a reduction in protein chain interactions and 
swelling of the corneocytes, and may subsequently increase in hydration to enhance the 
transdermal flux of the permeant (Nicolazzo et al., 2005). The amounts of aspalathin 
permeation in aqueous solutions of GRE and pure aspalathin across the human abdominal 
skin are shown in Table 2.5. Tape stripping was performed to obtain a compartmental 
distribution of aspalathin in the stratified layers of the skin. After 12 hours of dosing, 
aspalathin permeated into the stratum corneum (SC), epidermis and dermis (ED), and into 
the receptor fluid. Approximately 1.13 mg/ml of aspalathin in 5 mg/ml GRE and      
0.93 mg/ml pure aspalathin solution were applied onto the skin. A total of 0.08 % and  
0.09 % of aspalathin in the applied GRE and pure aspalathin solution permeated the skin, 
respectively. Figure 2.9 shows that the majority of the aspalathin that permeated the skin 
remains in the skin (0.07 % and 0.08 % of the applied dose of GRE and pure aspalathin 
solution, respectively) and was poorly absorbed into the receptor fluid fraction (0.01 % and 
0.01 % of the applied dose of GRE and pure aspalathin solution, respectively). Of the  
0.07 % of aspalathin in the GRE applied, 0.06 % of aspalathin distributed into SC and  
0.01 % distributed into ED. In comparison to GRE, less permeation occurred with the pure 
aspalathin solution, where 0.05 % and 0.03 % of aspalathin distributed into SC and ED, 
respectively. No significant difference in the skin distribution of aspalathin between GRE 
and pure aspalathin solution was observed. However, the amount of aspalathin in GRE 
permeated into the receptor fluid phase differs statistically from the amount of aspalathin 
that permeated in the pure aspalathin solution (P < 0.05). Batchelder et al. (2004) 
investigated the transdermal delivery of major catechins, epicatechin (EC), 
epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechin gallate (EGCG), 
in green tea from drug-in-adhesive patches and obtained 0.1 % permeation of 
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 Figure 2.9: The average percentage (%) of aspalathin that permeated the skin in green 
rooibos extract and aspalathin solution applied. (The outlier has been excluded). 
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Figure 2.10: Comparison of the absolute amount of aspalathin permeated in green rooibos 
extracts and aspalathin solutions. (The outlier has been excluded). 
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Table 2.5: Distribution data of aspalathin in green rooibos extract (GRE) and standard aspalathin (As) solution both at a concentration of 
approximately 1 mg/ml aspalathin. 
* Inconsistent value. 
a
 The amount of aspalathin distributed into the SC is significantly different to the amount distributed into ED, P < 0.05. 
b
 The amount of aspalathin that permeated into the receptor phase is significantly different from GRE and standard aspalathin solutions, P < 0.05. 
Stratum corneum  
(µg/cm2) 
Epidermis & dermis  
(µg/cm2) 
Whole skin  
(µg/cm2) 
Receptor  
(µg/cm2) 
Total absorbed  
(µg/cm2) 
 
GRE As GRE As GRE As GRE As GRE As 
Skin 
donor 
1 (n = 3) 
0.870 
1.094 
0.761 
0.586 
0.483 
0.347 
1.974* 
0.108 
0.078 
0.074 
0.048 
0.039 
2.844 
1.202 
0.840 
0.660 
0.531 
0.386 
0.183 
0.092 
0.088 
0.062 
0.074 
0.081 
3.027 
1.294 
0.928 
0.722 
0.605 
0.467 
Skin 
donor 
2 (n = 3) 
0.337 
0.307 
0.272 
0.530 
0.420 
0.420 
0.134 
0.082 
0.194 
0.130 
0.087 
0.130 
0.471 
0.389 
0.465 
0.661 
0.508 
0.550 
0.150 
0.127 
0.122 
0.099 
0.108 
0.086 
0.621 
0.516 
0.587 
0.759 
0.615 
0.636 
AV 
SD 
% RSD 
0.607 
0.348 
57.326 
0.464a 
0.086 
18.545 
0.428 
0.758 
177.015 
0.085a 
0.039 
45.996 
1.035 
0.938 
90.612 
0.549 
0.103 
18.828 
0.127b 
0.036 
28.125 
0.085b 
0.016 
19.273 
1.162 
0.958 
82.454 
0.634 
0.103 
16.186 
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the 1.35 mg/cm2 of green tea extracts applied, which was also equivalent to the percentage 
absorbed after intragastric administration of green tea extracts in rats. Compared to the 
findings of Batchelder et al. (2004) aspalathin has two-times the skin permeation of green 
tea catechins. Figure 2.10 is a plot of aspalathin distribution data. The amount of aspalathin 
in whole skin represents the sum of aspalathin in SC plus ED. The total absorbed is the 
total amount of aspalathin in total skin plus the receptor fluid fraction. Attention is drawn 
to the extraordinarily high value produced by GRE at the epidermis and dermis (ED) phase 
(marked *). Nonetheless, no significant difference in aspalathin permeation was detected 
between including and excluding this particular value (P < 0.05). 
 
Approximately 1 mg/ml of aspalathin was applied onto the skin in this permeation 
experiment. By substituting kp determined from Eq. 3 and the applied concentration of 
aspalathin into Eq. 2 a projected flux of aspalathin from an aqueous solution across the 
skin may be calculated as follow: 
 
J = kpcapp 
= 1.52 x 10-4 cm/h x 1 000 µg/ml 
= 0.152 µg/h/cm2 
 
permeation experiment) a theoretical aspalathin steady state flux after 12 hours of 
approximately 1.823 µg/cm2 is obtained. This predicted value is higher than the value 
obtained from this experiment. This may be explained by that this estimated flux is 
obtained by assuming the flux of aspalathin has reached the steady state, yet, the flux of 
aspalathin might have not reached the steady state in the 12 hours of the diffusion 
experiment to generate the estimated value. Because aspalathin is a polar compound 
possessing as many as nine ionisable hydroxyl units available for hydrogen-bond 
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formation and interaction with cellular components of the skin, its transport across the skin 
was further hindered and dramatically decreased the diffusion coefficient. In addition, 
aspalathin may oxidise to the two flavonones dihydro-orientin and dihydro-iso-orientin, 
which may have occurred during the permeation experiment. Nevertheless, aspalathin is 
only one of the many flavonoid antioxidants in rooibos tea, permeation of other flavonoid 
compounds that contribute to the health benefit of rooibos tea were also observed by 
HPLC.  
 
2.4 Conclusion 
Aspalathin is one of the major flavonoid components of rooibos comprising approximately 
20 % of the crude extract. Degradation of the compound occured in solution and was found 
more stable in a phosphate buffer system buffered between pH 5 and pH 6 with less than  
30 % loss over 14 hours. Aspalathin is hydrophilic, soluble in water and exhibits an 
octanol/water partition coefficient (Kow) below the value for optimal partition behaviour. 
Aspalathin was only detected in one of the two commercial skin care products amounting 
to less than 0.1 % of 1 g of cream analysed and a permeation experiment on the product 
was thus not considered feasible. In the permeation experiments of GRE and pure 
aspalathin solution, aspalathin accumulated mostly in the stratified layers of the skin, rather 
than permeating into the receptor fluid. Less than 0.1 % of aspalathin from the total dose 
applied was absorbed transdermally. This is comparible to the percentage permeation of 
green tea catechins observed by Batchelder et al. (2004). Approximately 80 % of the total 
aspalathin absorbed was distributed in the stratum corneum. Since more hydrolytic 
activities occur in the deep viable epidermis and less in the stratum corneum (Mavon et al., 
2004), aspalathin accumulation in the stratum corneum may be desirable in the topical use 
of rooibos. 
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CHAPTER 3. IN VITRO INTESTINAL EPITHELIAL TRANSPORT OF 
ASPALATHIN ACROSS CACO-2 CELL MONOLAYERS  
 
3.1 Introduction 
Orally delivered compounds of foods and drugs encounter the gastrointestinal tract as the 
first barrier to absorption and have to pass across the intestinal epithelium in order to be 
transferred to the whole body (Carrière et al., 2001). Tea of any sort is a beverage widely 
consumed throughout the world. There have been studies performed on human subjects 
indicating that flavonoids, in general, are absorbed to an appreciable amount through rapid 
absorption process, and remain relatively stable in the luminal fluid (Kuo, 1998). A study 
performed by Kuo (1998) suggests that flavonoids adopt rapid diffusional transport as their 
main route of absorption. It has also been suggested that the intestinal cells have the ability to 
accumulate flavone (Kuo, 1998 and Tammela et al., 2004). In order to determine the required 
level of flavonoid intake for maximum health-promoting effects, some knowledge of the 
potential of oral absorption of these compounds is essential. Amongst the in vitro systems 
employed to predict oral drug bioavailability in humans, the most commonly used epithelial 
cell line is Caco-2 monolayers, which has become regarded as the best model in terms of 
throughput and reliability (Karlsson et al. 1999, Krishna et al., 2001, Youdim et al., 2003). 
Studies have shown that there is a good correlation between permeability across the Caco-2 
cell monolayers and the oral absorption in humans (Krishna et al., 2001).  
 
3.2 Comparison of in vivo and in vitro human intestinal epithelia 
3.2.1 Anatomy and physiology of the small intestine 
The human intestine is estimated 2 – 6 m long and is divided into three sections, namely, the 
duodenum, the jejunum, and the ileum, comprising 5 %, 50 %, and 45 % of the length, 
respectively (Balimane and Chong, 2005). The biological and physiological parameters of the 
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human gastrointestinal tract are listed in Table 3.1 below (Balimane and Chong, 2005). 
Approximately 90% of all absorption in the gastrointestinal tract occurs over the length of the 
small intestine (Stoll et al., 2000) as its surface area has various projections that drastically 
increase the potential surface area for digestion and absorption. The valve-like circular folds 
encircling the entire intestinal lumen are estimated to increase the surface area of the small 
intestine threefold (Balimane and Chong, 2005). The presence of villi and microvilli (Figure 
3.1) further increase the surface area by 30-fold and 600-fold, respectively (Balimane and 
Chong, 2005). The uptake of substances occurs mainly in the duodenum and jejunum due to, 
among others, the decrease in size and the number of circular folds, villi and microvilli in the 
distal ileum (Stoll et al., 2000). 
 
Table 3.1: Biological and physiological characteristics of the human gastrointestinal tract 
(Balimane and Chong, 2005). 
Gastrointestinal 
segment 
Surface area (m2) Segment length (cm) pH of segment 
Stomach 3.5 0.25     1.0 – 2.0 
Duodenum 1.9 ~35 4.0 – 5.5 
Jejunum 184.0 ~280 5.5 – 7.0 
Ileum 278.0 ~420 7.0 – 7.5 
Colon and rectum 1.3 ~150 7.0 – 7.5 
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Figure 3.1: Villi and microvilli increase the absorptive surface area of the small intestine 
(re-drawn from http://www.emc.maricopa.edu/faculty/farabee/BIOBK/BioBookDIGEST.html). 
 
The main functions of the small intestine are the selective absorption of major nutrients and 
to serve as a barrier to digestive enzymes and ingested foreign substances. The intestinal 
epithelial cells are heterogenous in nature and include enterocytes or absorptive cells, goblet 
cells (mucin secreting cells), endocrine cells, paneth cells, M cells, and tuft and cup cells 
(Shah et al., 2006). Enterocytes are the most abundant epithelial cells that are responsible for 
the majority of the absorption of nutrients and drugs in the small intestine. These cells are 
polarized, having distinct apical and basolateral membranes that are linked to each other by 
tight junctions (Balimane and Chong, 2005).  
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3.2.2 Pathways of intestinal absorption 
Absorption of molecules and substances across the intestinal epithelium occurs mainly by 
concentration gradient driven passive diffusion via the cell membrane of enterocytes 
(transcellular) (Figure 3.2A), or via the tight junction between the enterocytes (paracellular), 
(Figure 3.2B). The passive diffusion transcellular route diffusion is related to lipophilic 
molecular properties, and the paracellular pathway is mainly size (molecular weight (MW), 
or volume) and charge-dependent (Ungell, 2004). Lipophilic substances can rapidly and 
completely partition from the luminal fluid and distribute into the cell membranes of the 
intestinal epithelium (Artursson et al., 2001). Slowly and incompletely passively absorbed 
hydrophilic drugs and peptides distribute poorly into the cell membranes and are transported 
through the water-filled pores of the paracellular route (Artursson et al., 2001 and Shah et al., 
2006). However, absorption via this route is generally low as the intercellular tight junctions 
restrict free transepithelial movement in the intercellular spaces between epithelial cells 
(Chan et al., 2004). Moreover, the surface area of the brush border membrane is >1000-fold 
larger than the paracellular surface area, thus the larger surface area of the cell membrane 
may compensate for the differences in partitioning between the cell membranes and the 
extracellular fluid allowing the hydrophilic substance to be transported in equal amounts by 
the paracellular and the transcellular routes (Artursson et al., 2001). Substances having 
similar chemical structures as those of certain nutrients and vitamins can be transported 
across the intestinal epithelium by specific transporters/carriers (Shah et al., 2006) (Figure 
3.2C). This type of transport is often partly by carrier-mediated and partly by passive routes. 
Carrier-mediated transport is saturable, thus the contribution of the passive route will 
increase with increasing dose (Artursson et al., 2001 and Shah et al., 2006). The plasma 
membranes of the epithelial cells possess active efflux mechanisms that play a critical role in 
limiting absorption and accumulation of potentially toxic substances in epithelial cells (Chan 
et al., 2004). Figure 3.2D demonstrates substances being extruded by the efflux transporters, 
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e.g. the P-glycoprotein (Pgp), multidrug resistance- (MDR) and multidrug 
resistance-associated protein-type (MRP) transporters, back into the intestinal lumen (Chan 
et al., 2004 and Hunter and Hirst, 1997). Substances present in high concentrations in the 
blood may undergo active blood-to-lumen secretion by these plasma membrane efflux 
transporters (Figure 3.2E). In addition to efflux pumps, the transcellular route of absorption 
exposes compounds to intracellular metabolic systems. Brush-border enzymes e.g. lactase, 
sucrase-isomaltase, and dipeptidylpeptidase IV, and cytochrome P450 (CYP)-mediated 
metabolic systems (phase I metabolism) in the small intestine plus other intracellular 
metabolic systems, such as phase II conjugation enzymes, may yield metabolites that are 
substrates for efflux pumps (Figure 3.2F and G) (Hauri, 1996, Suzuki and Sukiyama, 2000 
and Chan et al., 2004). Finally but not the least, the vesicular transport (transcytosis) from 
the apical to the basolateral side of the intestinal epithelium (Figure 3.2H) is considered as a 
route for highly potent drugs such as peptide antigens. This transport pathway is of limited 
value due to its low transport capacity and the presence of proteolytic enzymes limit this 
pathway as a general drug transport route (Artursson et al., 2001 and Shah et al., 2006).  
 
 
Figure 3.2: Routes of drug transport. (A) Passive transcellular absorption across intestinal 
epithelium. (B) Paracellular absorption mediated by tight junctions. (C) Carrier-mediated 
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transcellular transport at the apical and/or basolateral membranes. (D) Efflux transporter at 
the apical membrane may actively drive compounds back into the intestinal lumen thus 
restricting their absorption into the blood. (E) Apical efflux transporters that facilitate 
intestinal clearance of compounds that are already present in blood. (F) Intracellular 
metabolising enzymes may modify compounds before they enter the blood. (G) Apical efflux 
transporters and intracellular metabolising enzymes may co-ordinately metabolise and 
excrete compounds, forming an effective barrier against intestinal absorption. (H) 
Transcellular vesicular transport (modified from Chan et al., 2004; Hunter and Hirst, 1997). 
 
3.2.3 The in vitro Caco-2 cell model for transport study 
Unlike enterocytes, human tumour cells grow rapidly into confluent monolayers that provide 
an ideal cell culture model system for the rapid assessment of the intestinal permeability of 
xenobiotics (Balimane and Chong, 2005). The human adenocarcinoma cell line Caco-2 was 
originally isolated from a moderately well-differentiated human colon adenocarcinoma by 
Fogh and co-workers (1997), and has been developed as a model of intestinal epithelium 
(Gharat et al., 2001 and Isoda et al., 2006). These cells are able to spontaneously polarise and 
differentiate in long-term cultures in vitro to form monolayers that exhibit morphological and 
functional characteristics of enterocytes (Carrière et al., 2001). When confluent, the cells 
polarise and join by tight junctions, with well developed and organised microvilli on the 
apical membrane. The cells start to express several enzymatic activities e.g. brush border 
enzymes alkaline phosphotase and dipeptidyl peptidase, typical of the small intestine 
(Carrière et al., 2001; Basson and Hong, 1996). Polarized expression of several transport 
systems for sugars, amino acids, peptides and P-glycoprotein efflux transporters also follow 
the differentiation of Caco-2 cells (Yamashita et al., 2000 and Shah et al., 2006). Thus, 
Caco-2 cells have been used widely to study the effects and metabolism of natural and 
synthetic compounds at the intestinal level in addition to their transport through the epithelial 
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barrier. The Caco-2 cell line exhibits both characteristics of the small intestine and that of the 
colonocytes (Ranaldi et al., 2003 and Tammela et al., 2004). Several permeability 
characteristics such as the paracellular barrier of the colon present in Caco-2 cell monolayers 
is much higher than that of the small intestine epithelium, which unfortunately, results in the 
underestimation of the systemic bioavailability of paracellularly transported compounds 
(Versantvoort et al., 2002). Nevertheless, Caco-2 monolayers can be used as an absorption 
model to predict the intestinal absorption of compounds, to investigate their mechanism of 
transport, and as an in vitro model for studying the functionality of the carrier-mediated 
transport in the small intestine (Versantvoort et al., 2002). 
 
3.2.4 In vitro/in vivo correlations 
When using in vitro systems to gain information about drug permeability across the small 
intestine, the experimental conditions should reflect as closely as possible the real in vivo 
conditions (Youdim et al., 2003). Many drug molecules are ionisable and may coexist in both 
their charged and uncharged forms in solution. At physiological pH 7.4, these drug molecules 
are predominantly ionised. The pH hypothesis postulates that the diffusion of a molecule 
across lipid membranes is through its uncharged form and that the charged form is 
impermeable. Luminal pH values vary throughout the gastrointestinal tract. Measurement of 
the “acid microclimate” on the surface of intestinal epithelial cells (intact with mucus layer) 
in rats  reveals that the pH value on the apical side of the cells range from 6-8, whereas the 
values on the basolateral side was ~7.4 (Figure 3.3) (Said et al., 1986 and Youdim et al., 
2003). Yamashita and co-workers (2000) employed gradient-pH conditions i.e. pH 6.0apical – 
pH 7.4basolateral in characterising drug permeability. In comparison to iso-pH condition i.e. pH 
7.4apical – pH 7.4basolateral, weak acids were found more permeable under the gradient-pH 
condition, whereas weak bases showed no differences in permeability under the two 
conditions. Nonetheless, for weak acids, both passive diffusion and active transport are 
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dependent on the concentration of protons in the apical solution. Thus, for an acid neither the 
presence nor absence of a pH gradient by itself is guiding the interpretation (Ungell, 2004).  
 
In contrast to the extensively folded jejunum the Caco-2 monolayers are flat, representing 
only a fraction of the anatomical surface area of the intestine, the villi tips (Figure 3.3). This 
supports the hypothesis that only a fraction of the anatomical surface area of the intestine, i.e. 
the villi tips, participate in the absorption of drugs that adopt passive transcellular route 
(Artursson et al., 2001). On the other hand, slowly and incompletely absorbed substances 
were found to be transported 30- to 80-fold slower in rate in the Caco-2 monolayers than in 
the human jejunum (Lennernäs et al., 1996). This phenomenon may possibly be a result of 
differences in the permeability of the paracellular pathway and absorptive surface area 
between the Caco-2 monolayers and the human jejunum as there are fewer water-filled pores 
in the tight junctions in the Caco-2 monolayers. In vivo, substances with lower permeability 
will remain in the intestinal lumen longer before they are absorbed. This retention allows 
diffusion of the substance further down the length of villi as compared to substances having 
higher permeability which are rapidly and completely absorbed through the villi tips. This 
diffusion results in an increase in the absorptive area and, in addition, allows a fraction of the 
substance to be absorbed through the leakier paracellular pathway in the crypt region. Other 
potential sources of variability may arise from experimental conditions and the specific cell 
line (Artursson et al., 2001).  
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Figure 3.3: A comparison of in vivo extensively folded intestinal epithelia and in vitro flat 
Caco-2 cell monolayer, and barriers across which drugs must pass to reach the basolateral 
phase (Youdim et al., 2003). 
 
3.3 In vitro Caco-2 cell monolayer transport study 
3.3.1 Caco-2 cell culture and setup for transport studies 
Various methods of growing and carrying out transport experiments with Caco-2 monolayers 
have been described and employed. In general, cells are grown on a porous support, such as 
polycarbonate filters, for about 15 – 21 days in a cell culture medium containing Delbecco’s 
Modified Eagle Medium supplemented with 20 % foetal bovine serum, 1 % non-essential 
amino acids and 2mM L-glutamin (pH 7.4 mimicking the physiological pH). The cells are 
grown at 37 °C in 5 % carbon dioxide at a relative humidity of 95 %. Transport experiments 
are usually carried out after 21 days of culturing.  
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Figure 3.4: The in vitro cell culture model (modified from Youdim et al., 2003; During and 
Harrison, 2005). 
 
3.3.2 Determination of the apparent permeability coefficient (Papp) 
The rate of dissolution and solubility (determining how fast the drug reaches its maximum 
concentration (C) within the luminal intestinal fluid), and the permeability coefficient (P) 
(determining the rate at which the drug will cross the intestinal wall to reach the portal blood 
circulation) are properties that influence the ease with which a drug can be absorbed (Youdim 
et al., 2003). Together, these factors comprise Fick’s first law, describing the rate of transport 
(flux) (Jwall) of a drug across the intestinal wall which can be expressed as follows (Youdim et 
al., 2003) (cf. Eq. 1, Chapter 2):  
 
Jwall = P x C                                                            (1) 
 
When examining drug permeability across in vitro cell models, determination of the apparent 
permeability coefficient (Eq. 2, Artursson, 2001) derived from Fick’s first law may be used 
by taking into account the starting concentration (Ungell, 2004):  
 
Papp = dQ/dt (1/(A.60.C0))                                                (2) 
 
Where: Papp  = apparent permeability coefficient (cm/s), 
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 dQ/dt  = permeability rate (amount permeated per minute), 
 A  = diffusion area of the monolayer (cm2), 
             C0 = initial concentration of the marker molecule in the apical compartment. 
 
The apparent permeability coefficient (Papp) quantifies the transport of a drug molecule in a 
two compartmental system (Ekmekcioglu, 2002). The apical-to-basolateral permeability of a 
substance through the epithelial cell layer is measured as an increase in the concentration of 
the substance in the basolateral phase over time (Braun et al., 2000) 
 
3.3.3 Measurement of transepithelial electrical resistance (TEER) 
Tight junctions play a critical role in epithelial cell biology by forming a selective 
permeability barrier in the spaces between adjacent epithelial cells and in the maintenance of 
compositional asymmetry in the cell (Isoda et al., 2006). The tight junctions provide a route 
of transport of ions across the intestinal epithelial cells. Hydrophilic drugs and peptides, in 
general, are assumed to adopt this route of transport (passive paracellular pathway) 
(Artursson et al., 2001). Thus, measurement of TEER may reflect the ion permeability of the 
cell monolayers, where an increase in transport of ions is associated with opening of the tight 
junctions (increase in diameter) resulting in a decreased TEER. Measurement of TEER also 
evaluates the integrity of epithelial monolayers and is a sensitive method widely used for 
screening possible membrane perturbents resulting from cell injury (Isoda et al., 2006).  
 
3.4 Pheroid technology 
Various methods have been used to increase the bioavailability of drugs. Some involves the 
use of specific chemicals to facilitate the absorption of the drug by temporarily increasing the 
membrane permeability (Ghafourian et al., 2004). Pheroid technology (further referred to as 
Pheroid or Pheroids, previously known as EmzaloidTM technology) is a patented system that 
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involves the use of a unique submicron emulsion formulation. A Pheroid is a stable structure 
within a system that is flexible in terms of morphological, structural, size, and functional 
manipulation. It is a composite of mainly ethyl esters of plant and essential fatty acids, such 
as linoleic acid, linolenic acid, and oleic acid, emulsified in water saturated with nitric oxide 
(NO) (Saunders et al., 1999). Several fatty acid constituents in Pheroids are therapeutically 
beneficial in maintaining cell membrane integrity, energy homeostasis, and modulating the 
immune system through leukotrins and prostaglandins (Grobler, 2004). Pheroid technology 
was first discovered when it was used as a basic formulation which led to the remission of 
psoriasis (Schlebush, 2002). Three types of Pheroids, namely, (i) lipid bilayer vesicles in both 
nano- and micrometer size range, (ii) micro-sponges, and (iii) depots or reservoirs that 
contain pro-Pheroids, have since been formulated in attempt to increase entrapment 
capabilities, enhance rate of transport, delivery, and stability. The size and shape of vesicles 
vary depending on the type of formulation, with lipid bilayers of 30 – 80 nm, micro-sponges 
of 0.5 – 5 µm, and the size of depots varies with the amount of pro-Pheroid contained within 
(Grobler, 2004). The entrapment of drugs in the three-phased Pheroid system (water, fatty 
acid, and nitric oxide) proposes to create a safer and more effective formulation in drug 
delivery (Grobler, 2004). 
 
Pheroid technology is currently being studied for its drug penetration enhancing effect. 
During the transport experiment of green rooibos extracts and its pure compound aspalathin, 
this technology was employed as one of the possible mechanisms to enhance intestinal 
absorption and it was kindly provided by the Department of Pharmaceutics, North-West 
University (Potchefstroom campus).  
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3.5 MATERIALS AND METHODS 
3.5.1 Materials 
The green rooibos extract (GRE) (EURO Ingredients) was provided by Dr. E. Joubert. The 
aspalathin pure compound was obtained from PROMEC (Tygerberg, South Africa). Pheroids 
containing green rooibos aqueous extracts were prepared and provided by North-West 
University. HPLC grade acetonitrile (CH3CN) and 0.1 % acetic acid (CH3COOH) were 
obtained from BHD Laboratory Supplies (Poole, UK). Potassium dihydrophosphate 
(KH2PO4), disodium hydrogen phosphate dihydrate (Na2HPO4·2H2O), and sodium chloride 
(NaCl) were supplied by Merck (Midrand, South Africa) (ISO 9001 certified). Cryopreserved 
Caco-2 cells were obtained from American Type Culture Collection (Virginia, USA). 
Dulbecco’s Modified Eagle’s Medium (DMEM), Hank’s Balanced Salt Solution (HBSS) (pH 
7.4), Dulbecco’s Phosphate Buffered Saline (DPBS) with calcium and magnesium (pH 7.4), 
trypsin-versine solution, 1 % non essential amino-acids (NEAA), and 1 % 
penicillin/streptomycin mixture (10 000 units penicillin/ml and 10 000 µg streptomycin/ml) 
were all supplied by Bio Whittaker (Walkersville, Maryland). Foetal bovine serum (10 %) 
was obtained from Delta Bioproducts, Kempton Park, South Africa. Double distilled water 
was prepared by Milli-Q water purification system (Millipore, Milford, USA), which was 
used throughout the study.  
 
3.5.2 High performance liquid chromatography (HPLC) method for the analysis of 
aspalathin 
The method for analysis of aspalathin and validation of HPLC procedure are described in 
section 2.2.2 of Chapter 2. Pheroid samples were analysed by HPLC as is.  
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3.5.3 Determination of stability of aspalathin 
3.5.3.1 Stability in transport medium 
Gastrointestinal assays using Caco-2 cell monolayers is normally carried out with DMEM 
supplemented with bovine serum albumin (BSA) as the growth medium that provides 
nutrients for culturing of cells, and as well as the receiver buffer medium in the basolateral 
phase. The use of BSA is usually recommended to reduce unspecific binding to plastics, 
filters or accumulation within the lipid bilayer or intracellularly (Ungell, 2004), and may 
improve permeability by providing a more favourable “sink condition” for partitioning of 
lipophilic compounds, mimicking the properties of physiological presence of albumin within 
the capillary lumen (Youdim et al., 2003). Phenolic compounds are renowned for their strong 
affinities for proteins to form both non-covalent and covalent association according to the 
size of the phenolic compound (Laurent et al., 2007). Kuo (1998) observed binding of 
flavonoids to extracellular proteins and to BSA in the incubation and led to impedance in 
transport and cellular accumulation of flavone in a dose-dependent fashion. In addition, a 
preliminary aspalathin transport experiment carried out using BSA supplemented DMEM 
showed interference in the recovery of aspalathin. Thus, an investigation on the stability of 
the aspalathin in DMEM is critical to eliminate possible compound-vehicle interaction. Three 
vehicle systems: (i) double distilled water, (ii) phosphate buffer system (PBS) (pH 7.4) 
(prepared as described in Chapter 2), and (iii) DMEM were used in determining the stability 
of aspalathin. Water serves as a control medium as rooibos tea is an aqueous extract of the 
rooibos plant, and the PBS serves as a possible alternative to DMEM as the receiver buffer 
medium in the basolateral phase. Solutions of approximately 120 µg/ml of aspalathin were 
prepared in each of the vehicle systems and left on the autosampler under room temperature 
25 °C for analysis by HPLC at hourly intervals. The peak areas of aspalathin at each hour 
were determined and plotted as a function of time (Figure 3.7). 
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3.5.4 In vitro transport study 
3.5.4.1 Preparation of test formulations for the transport study 
Three concentrations: 10.0 mg/ml, 5.0 mg/ml, and 1.0 mg/ml, of GRE dissolved in DPBS 
were prepared in a volume of 10 ml, respectively, to allow experimentation of each 
concentration done in triplicate. In a preliminary HPLC analysis of the green rooibos aqueous 
extracts 5.0 mg/ml green rooibos extracts contained approximately 1.0 mg/ml aspalathin 
(described in Chapter 2). Thus aspalathin solutions were prepared at 2.0 mg/ml, 1.0 mg/ml, 
and 0.2 mg/ml in 10 ml DPBS, respectively, to equate to the amounts of aspalathin contained 
in the three solutions of GRE. Pheroids containing GRE made up to 10.0 mg/ml, 5.0 mg/ml, 
and 1.0 mg/ml concentrations were prepared and provided by North-West University.  
 
3.5.4.2 Preparation of Caco-2 cell monolayers 
3.5.4.2.1 Culturing of Caco-2 cells 
Cryopreserved Caco-2 cells obtained from American Type Culture Collection were thawed in 
a water bath at 37 °C for one minute. The cells were then transferred to a 25 cm3 cell culture 
flask (Coring Costar Corporation, USA) containing 15 ml culture medium, pre-heated to 37 
°C. The cell lines were grown and maintained in culture medium consisting of DMEM 
containing 25 mM glucose, 3.7 g/L NaHCO3, supplemented with  10 % foetal bovine serum, 
1 % NEAA and a 1 % penicillin/streptomycin mixture (10 000 units penicillin/ml and 10 000 
µg streptomycin/ml). The cells were incubated in a CO2 incubator (Forma Scientific Inc., 
Marietta, Ohio, USA) at 37 °C in 5 % CO2 and an atmosphere of 95 % humidified air.  The 
medium was initially changed 24 hours after the reconstitution of cells, after which the 
medium was then changed every second day and trypsinated every week.  
 
3.5.4.2.2 Trypsination of the Caco-2 cells  
The culture flasks were macroscopically examined and only flasks with cells that had 
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reached confluence were used for the trypsination procedure (± every 7 days). HBSS, 
trypsin-versine solution, and culture medium were heated in a water bath at 37 °C. These 
selected cell culture flasks and the pre-heated solutions were transferred to a laminar airflow 
cabinet. The cells in the flask were rinsed twice with HBSS and 0.5 ml of the trypsin-versine 
solution was poured onto the cells and distributed evenly to cover the cell monolayer. The 
flask was then incubated for 10 minutes at 37 °C in 5 % CO2 in an atmosphere of 95 % 
humidified air. After incubation the flask was transferred to the laminar airflow cabinet and 
inspected macroscopically whether all the cells were detached, and approximately 2 ml of the 
warm medium (37 °C) was then added to the down surface of the flask. This cell suspension 
was diluted by adding it to warm (37 °C) culture medium in a tube and agitated with a 
Pasteur pipette. The flask was rinsed with 1 ml of warm   (37 °C) culture medium to ensure 
all the cells were removed from the flask. Three 25 ml flasks were transferred to the laminar 
airflow cabinet and marked with the date and new passage number. An amount of 15 ml of 
the cell suspension was added to each of the three 25 ml culture flasks and incubated. 
 
This trypsination procedure was repeated every week to prevent overgrowth of the cells in 
the flasks until they were used in the experiments 
 
3.5.4.2.3 Seeding and culturing of Caco-2 cell monolayers on 6-well filter plates 
Caco-2 cells were seeded (Figure 3.5A) on tissue culture treated polycarbonate filters (area = 
4.70 cm2) in Costar Transwell 6-well plates (Corning Costar Corporation, USA). A cell 
suspension was obtained in the same way as described in the trypsination process (previous 
section). The cells were counted on a hemacytometer and diluted until a concentration of      
1.77 x 104 cells/ml was reached. The culture medium consisted of DMEM supplemented 
with 10 % foetal bovine serum, 1 % NEAA and 1 % penicillin/streptomycin fungizone 
solution (10 000 units penicillin/ml, 10 000 µg streptomycin/ml and 25 µg fungizone/ml). 
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The medium was added to both the apical (2.5 ml) and basolateral (2.5 ml) compartments 
and was changed every second day under aseptic conditions. The cell cultures were kept in 
an incubator at 37 °C in 5 % CO2 and an atmosphere of 95 % humidified air. The filters were 
used for drug transport measurements 21 days after seeding. 
 
3.5.4.2.4 Measurement of TEER 
The integrity of the cell monolayers was assessed by the measurement of transepithelial 
electrical resistance (TEER) (Figure 3.5B). Caco-2 cell monolayers exhibiting a TEER value 
of more than 160 Ω cm2 were used within 30 days post-seeding. TEER was measured using a 
Millicell ERS meter (Millipore, USA) before and after the experiment. 
 
3.5.4.3 Transport of aspalathin across Caco-2 cell monolayers 
The growth medium was removed from the basolateral chamber and replaced with 2.5 ml 
DPBS with calcium and magnesium buffered at pH 7.4 and incubated for another 30 min. 
After the incubation the growth medium from the apical side was removed and replaced with 
2.5 ml of GRE, pure aspalathin solution, and Pheroids containing green rooibos aqueous 
extract, respectively (Figure 3.5 C and D). Samples of 200 µl were taken at time intervals of 
0, 20, 40, 60, 90, and 120 minutes from the basolateral side (Figure 3.5E) after incubation of 
the test formulations on the apical side of the monolayers. The samples withdrawn from the 
basolateral side were immediately replaced with an equal volume of DPBS. All experiments 
were done in triplicate in a humidified atmosphere of 95 % air and 5 % CO2 at 37 °C.  
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Figure 3.5: Procedures of in vitro transport across Caco-2 cell monolayers. (A) Seeding of 
Caco-2 cells. (B) Measurement of TEER. (C) Removal of growth medium. (D) Loading of 
test formulation onto Caco-2 cell monolayers. (E) Sampling from the basolateral phase at 
predetermined time intervals (photos provided by A.M. Viljoen).  
 
3.5.4.4 Sample analysis 
Results obtained from HPLC were corrected for dilution and expressed as cumulative 
transport (% of initial dose) and apparent permeability coefficients (Papp) of aspalathin in 
GRE, pure aspalathin solution, and Pheroids containing green rooibos aqueous extract, 
respectively, were calculated according to the following equation (detailed previously):   
Papp = (dQ/dt) (1 / (A.60.C0)) 
 
3.5.4.5 Statistical analysis 
The experiments were done in triplicate and the data expressed as means ± standard deviation. 
Differences between mean values were analysed by means of one-way analysis of variance 
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(ANOVA). The difference between the three test formulations was compared and a P-value < 
0.05 was considered significantly different. 
 
3.6 RESULTS AND DISCUSSION 
3.6.1 Stability of aspalathin in transport medium 
Aspalathin solutions prepared in (i) double distilled water (control), (ii) PBS (pH 7.4), and 
(iii) DMEM were sampled and analysed at room temperature 25 °C at hourly intervals over 
ten hours by HPLC. Figure 3.6 is a plot of aspalathin peak area over time demonstrating 
degradation/interference of aspalathin in/with the various vehicles.  
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Figure 3.6: Loss of aspalathin over time in vehicles of (i) double distilled water, (ii) 
phosphate buffer solution (PBS) (pH 7.4), and (iii) Dulbecco’s Modified Eagle’s Medium 
(DMEM). 
 
From Figure 3.6 it is noted that there was a general loss of aspalathin in all three of the 
vehicle systems. The decline in the percentage of aspalathin is highest in DMEM, exhibiting 
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a rapid logarithmic decline to virtually zero detection of aspalathin at the tenth hour. 
Approximately 90 % and 74 % of aspalathin in double distilled water and PBS, respectively, 
remained at the tenth hour. Although aspalathin degradation was less dramatic in the double 
distilled water and PBS, degradation was still to an appreciable amount accounting for the 
fact that the decline is a function of time in hours. From these results it can be seen that 
aspalathin is an unstable compound once in solution. Although Tammela and co-workers 
(2004) did successfully employ DMEM in their transport study, results from this assay 
confers the use of PBS as the alternative receiver fluid buffer medium to DMEM for the 
transport of aspalathin. The aspalathin transport experiment was done over 2 hours where 
less than 5 % loss of aspalathin could occur (Figure 3.6). To further reduce the rate of 
degradation, samples of the experiment were stored at -20 °C immediately after collection. 
 
3.6.2 Transport of aspalathin in the green rooibos extracts 
The cumulative (% of initial dose) transport of aspalathin in GRE at three different 
concentrations is shown in Table 3.2. The experiment was carried out over 2 hours and time 
is expressed in minutes. Each value is expressed as means ± standard deviation (SD) of three 
experiments (n = 3). The Papp is also expressed as means ± SD of the average percentage 
transport.  
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Table 3.2: The cumulative (% of initial dose) transport ± SD of aspalathin in green rooibos 
extract across the Caco-2 cell monolayers.  
Average % transport ± SD  
Time (min) 
 
Extract 1 
(10.0 mg/ml) 
Extract 2 
(5.0 mg/ml) 
Extract 3 
(1.0 mg/ml) 
0 
20 
40 
60 
90 
0.00 
81.24 ± 7.70 
94.79 ± 6.99 
99.74 ± 9.85 
92.80 ± 3.03 
0.00 
9.27 ± 2.14 
10.53 ± 3.04 
11.65 ± 2.07 
12.70 ± 2.05 
0.00 
12.47 ± 1.03 
16.27 ± 6.15 
16.35 ± 7.78 
17.17 ± 0.45 
120 96.96 ± 8.95 14.16 ± 1.22 18.13 ± 1.85 
Papp (cm/sec) 20.93 ± 3.61 x 10-06 a 3.49 ± 1.45 x 10-06 b 4.00 ± 0.42 x 10-06 b 
 
a,b
 Papp is statistically significantly different to one another, P < 0.05. 
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Figure 3.7: Plot of the cumulative transport of aspalathin in green rooibos extracts over time. 
 
Figure 3.7 is a plot of the average percentage transport of aspalathin as a function of time. 
From the graph it can be seen that transport of aspalathin in GRE 1 (10.0 mg/ml) was rapid 
and linear at the first 20 minutes, reaching a plateau after 60 min (1 hour). A total of 80 % of 
aspalathin transported occurred within 20 minutes and reached close to 100 % transport of 
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aspalathin of the administered dose at 120 minutes (2 hours). The average percentage of 
aspalathin in GRE 2 (5.0 mg/ml) and GRE 3 (1.0 mg/ml) transported were found 
considerably less than that in GRE 1. All three extracts showed similar patterns of flux of 
aspalathin reaching plateau after 60 min but at a higher rate in the case of GRE 1. This may 
probably be due to a concentration dependent factor in the transport of aspalathin i.e. the 
higher the concentration the greater the amount transported where the driving force of flux 
may be greater. Consequently, the Papp of aspalathin in GRE 1 (20.93 ± 3.61 x 10-06 cm/s) is 
the highest of the three concentrations tested, reflecting a rapid and almost complete apical to 
basolateral transport. Papp of aspalathin in GRE 2 and GRE 3 are similar (P > 0.05), which are 
3.49 ± 1.45 x 10-06 cm/s and 4.00 ± 0.42 x 10-06 cm/s, respectively, corresponding to a slower 
rate of transport of aspalathin across the Caco-2 cell monolayers and are statistically 
significantly different to that of GRE 1 (P < 0.05). This difference may be due to that 
aspalathin transport was rapid in the first 20 min of the experiment in   GRE 1. 
 
3.6.3 Transport of aspalathin in pure aspalathin solution 
Table 3.3 presents the average percentage (%) transport of aspalathin in pure aspalathin 
solutions buffered at three concentrations. Each value is expressed as means ± SD of three 
experiments (n = 3). The Papp is also expressed as means ± SD of the average percentage 
transport.  
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Table 3.3: The cumulative (% of initial dose) transport ± SD of aspalathin in a pure 
aspalathin solution across the Caco-2 cell monolayers.  
Average % transport ± SD  
Time (min) 
 
Aspalathin 1 
(2.0 mg/ml) 
Aspalathin 2 
(1.0 mg/ml) 
Aspalathin 3 
(0.2 mg/ml) 
0 
20 
40 
60 
0.00 
68.12 ± 8.20 
66.17 ± 6.78 
71.59 ± 11.97 
0.00 
0.86 ± 0.03 
3.19 ± 0.98 
4.11 ± 1.01 
0.00 
4.02 ± 8.10 
2.06 ± 3.75 
2.68 ± 3.19 
90 
120 
67.74 ± 7.01 
79.03 ± 0.38 
4.50 ± 0.76 
7.54 ± 0.71 
2.76 ± 3.45 
4.66 ± 4.70 
Papp 15.34 ± 1.66 x 10-06 a 2.48 ± 0.03 x 10-06 b 0.91 ± 0.37 x 10-06 c 
a,b,c Papp is statistically significantly different to one another, P < 0.05. 
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Figure 3.8: Plot of the cumulative transport of aspalathin in a pure aspalathin solution over 
time. 
 
A plot of the average percentage transport of aspalathin versus time of the three pure 
aspalathin solutions is presented in Figure 3.8. Similar to what is observed in GRE 1 (Figure 
3.7) transport of aspalathin at 2 mg/ml (Aspalathin 1) is rapid and linear from 0 (zero) to 20 
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minutes. Although the aspalathin transport in Aspalathin 1 varied after 20 minutes to 120 
minutes, it seems to have reached a steady plateau. Less than 10 % of the administered dose 
of aspalathin was transported across the cell monolayers in Aspalathin 2 (1 mg/ml) and 
Aspalathin 3 (0.2 mg/ml). A similar trend in the plot of transport of aspalathin in the GRE 
and in the pure aspalathin solutions can be seen. A greater amount of aspalathin was 
transported in formulations at the highest concentrations (GRE 1 and Aspalathin 1), 
demonstrating once again that the absorption may be concentration dependent. In this 
experiment, the rate of transport of aspalathin was significantly different (P < 0.05) amongst 
the three solutions, where the Papp of aspalathin in Aspalathin 1, 2, and 3 are 15.34 ± 1.66 x 
10-06  cm/s, 2.48 ± 0.03 x 10-06 cm/s, and 0.91 ± 0.37 x 10-06 cm/s, respectively.  
 
3.6.4 Transport of aspalathin in Pheroids  
Table 3.4 is the average percentage (%) transport ± SD of aspalathin in Pheroids incorporated 
with GRE over 2 hours. Three concentrations of Pheroids were formulated. Results are 
expressed as means ± SD and value of Papp is expressed as means ± SD of the average 
percentage transport (n = 3).  
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Table 3.4: The cumulative (% of initial dose) transport ± SD of aspalathin in Pheroids across 
the Caco-2 cell monolayers.  
Average % transport ± SD  
Time 
 
Pheroid 1 
(10.0 mg/ml) 
Pheroid 2 
(5.0 mg/ml) 
Pheroid 3 
(1.0 mg/ml) 
0.00 
2.18 ± 0.97 
4.53 ± 0.21 
7.93 ± 0.40 
0 
20 
40 
60 
90 
120 
0.00 
2.61 ± 1.33 
3.94 ± 0.39 
5.91 ± 1.19 
5.48 ± 0.08 
6.04 ± 1.07 
0.00 
15.46 ± 4.02 
32.96 ± 3.03 
40.63 ± 4.68 
56.24 ± 0.10 
61.82 ± 0.71 
12.82 ± 1.04 
16.32 ± 1.13 
Papp 1.65 ± 0.12 x 10-06 a 18.62 ± 0.23 x 10-06 b 4.95 ± 0.27 x 10-06 c 
a,b,c Papp is statistically significantly different to one another, P < 0.05. 
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Figure 3.9: Plot of the cumulative transport of aspalathin in Pheroids over time. 
 
Pheroids were developed to act as permeation enhancer in drug delivery across biological 
membranes. The physicochemical properties of Pheroids have not yet been clearly 
characterised and its function as permeation enhancer has not completely been elucidated. It 
can be seen from Figure 3.9 that the pattern in the transport of aspalathin in Pheroids is quite 
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different to that observed in the GRE and the pure aspalathin solutions (P < 0.05). Transport 
of aspalathin in Pheroids was slow and steady and did not reach a plateau at the end of the 
experiment. A higher amount of aspalathin was transported in Pheroid 2 than in Pheroids 1 
and 3. The Papp determined for each concentration differs greatly from one another (P < 0.05), 
where 1.65 ± 0.12 x 10-06 cm/s, 18.62 ± 0.23 x 10-06 cm/s, and     4.95 ± 0.27 x 10-06 cm/s 
are Papp of Pheroid 1, 2, and 3, respectively. Compared to   Figure 3.7 and 3.8, Figure 3.9 
does not exhibit enhanced transport of aspalathin in the Pheroid technology across the 
Caco-2 cell monolayers in this experiment. 
 
3.6.5 Comparison of the apparent permeability coefficient (Papp) 
Figure 3.10 presents the Papp ± SD obtained for the transport of aspalathin from the three 
formulations at three different concentrations. The plot shows that Papp of aspalathin is a 
concentration dependent factor. This may be explained by the higher concentrations result in 
a greater driving force of diffusion. The Papp of aspalathin is higher in the GRE than in the 
pure aspalathin solutions. This may be explained by GRE being a mixture of numerous 
flavonoid glycosides and phenolic compounds that may affect the flux of aspalathin by e.g. 
increasing the driving force of diffusion or facilitating its transport across the Caco-2 cell 
monolayer. Table 3.5 presents the average Papp ± SD obtained for aspalathin in the various 
test formulations (n = 3). 
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Table 3.5: The apparent permeability coefficient of (i) GRE, (ii) pure aspalathin solutions, 
and (iii) Pheroids at three different concentrations. 
  Average Papp (x10-6) (cm/s) ± SD 
GRE 1 (10 mg/ml) 20.93  ± 3.61 
GRE 2 (5 mg/ml) 3.49  ± 1.45 
GRE 3 (1 mg/ml) 4.00  ± 0.42 
Aspalathin 1 (2 mg/ml) 15.34  ± 1.66 
Aspalathin 2 (1 mg/ml) 2.48  ± 0.03  
Aspalathin 3 (0.2 mg/ml) 0.91  ± 0.37 
Pheroid 1 (10 mg/ml) 1.65  ± 0.12 
Pheroid 2 (5 mg/ml) 18.62  ± 0.23 
Pheroid 3 (1 mg/ml) 4.95  ± 0.27 
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Figure 3.10: Comparison of the apparent permeability coefficient (Papp) of: (i) GRE, (ii) 
aspalathin solution, and (iii) Pheroids at three different concentrations. 
 
In a study conducted by Biganzoli et al. (1999), the Papp of 13 antibiotics with variable 
bioavailability in humans were obtained. On the basis of Papp they grouped the compounds 
into : (i) Papp values < 0.2 x 10-6 cm/s (bioavailability < 1 %); (ii) Papp values between 0.2 and 
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2.0 x 10-6 cm/s (bioavailability between 1 % and 90 %); (iii) Papp values > 2.0 x 10-6 cm/s 
(bioavailability > 90 %). Artursson et al. (2001) also found that completely absorbed drugs 
have a high permeability coefficient (Papp > 1 x 10-6 cm/s), whereas incompletely absorbed 
drugs had a low permeability coefficient (Papp < 1 x 10-7 cm/s) in the Caco-2 monolayer 
model. In this study the Papp of aspalathin obtained were all greater than     0.2 x 10-6 cm/s 
at the various concentrations and formulations tested suggesting that aspalathin may have a 
bioavailability up to or greater than 90 % depending on the concentration administered. This 
correlates with the findings by Kuo (1998) and Tammela et al. (2004) in the investigation on 
the transport of various flavonoids. To compare the amount of aspalathin available for 
absorption in a cup of rooibos tea (i.e. 3 mg described in Chapter 1 section 1.6.3) to the 
highest aspalathin concentration (2mg) applied to the Caco-2 cell monolayers for transport 
study, a greater than 90 % of aspalathin in a cup of rooibos tea is bioavailable. In addition, 
rooibos tea and green tea have a comparable amount of flavonoid contents and the latter 
exhibits greater inhibition on lipid peroxidation in vitro (described in the section 1.6.4 of 
Chapter 1). However, Zhang et al. (2004) conducted a transport study on the major green tea 
flavonoids i.e. epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and 
epigallocatechin gallate (EGCG), and found the Papp of each of the flavonoids were 1.39 ± 
0.082 x 10-7 cm/s, 1.49 ± 0.13 x 10-7 cm/s, 0.96 ± 0.15 x 10-7 cm/s, and 0.83 ± 0.24 x 10-7 
cm/s, respectively. Although green tea flavonoids exhibit good inhibitory effects on lipid 
peroxidaiton, their Papp would predict a bioavailability of less than 1 %. Thus, aspalathin may 
exhibit a good bioavailability in humans and that it can be absorbed to an appreciable amount 
to exhibit biological activities.  
 
3.7 Conclusion 
Many flavonoid compounds have been investigated for their in vitro transport across 
intestinal epithelium using Caco-2 cell monolayers. In this study, a chemical interaction was 
  80
observed between aspalathin and DMEM (pH 7.4) and almost caused complete degradation 
of aspalathin within hours. The DPBS may be an alternative to the DMEM for transport 
studies of flavonoids. Aspalathin has an absorption profile that is concentration dependent 
where almost 100 % transport of aspalathin was observed in GRE at 10 mg/ml. Better 
aspalathin absorption occurred in the GRE than in the pure aspalathin solutions and the 
incorporation of the Pheroid technology did not enhance the transport of aspalathin. The Papp 
of aspalathin in the GRE and in the pure aspalathin solution were all above    0.2 x 10-6 
cm/s, a value ten-fold greater than of that of the major green tea catechins obtained by Zhang 
et al. (2004), predicting a greater than 90 % bioavailability in vivo.  
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CHAPTER 4: CONCLUSION AND FUTURE PROSPECTIVE 
 
4.1 Summary and conclusion 
The in vitro percutaneous permeation and in vitro intestinal epithelial transport of 
aspalathin was investigated. Human female abdominal skin mounted onto vertical Franz 
diffusion cells and Caco-2 cell monolayers isolated and cultured from human colonic 
adenocarcinoma cells were used. Extracts of green (unfermented) rooibos and pure 
aspalathin solutions at various concentrations were put to tested.  
 Less than 0.1 % of aspalathin in the applied doses of green rooibos extract and pure 
aspalathin solution permeated the skin. 
 80 % of the permeated aspalathin was distributed in the stratum corneum. 
 Aspalathin was only detected in one of the two rooibos skin care products (cream). 
Less than 1 mg (0.1 %) of aspalathin was extracted from 1 g of the cream. Permeation 
study on these skin care products was therefore not considered feasible. 
 Transport of aspalathin across Caco-2 cell monolayers exhibited a concentration 
dependent behaviour. 
 Almost 100 % transport was observed at the highest concentration applied.  
 Better aspalathin transport was observed with the aqueous green rooibos extracts than 
with the pure aspalathin solution across the Caco-2 cell monolayers.  
 The apparent permeability coefficient (Papp) obtained for aspalathin was above 0.2 x 
10-6 cm/s which may predict a bioavailability of over 90 % in vivo. 
 The incorporation of the Pheroid technology did not positively enhance the transport 
of aspalathin across the Caco-2 cell monolayer. 
 A greater amount of aspalathin was transported across the Caco-2 cell monolayers 
than permeated into and through the skin. 
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4.2 Future prospective  
The benefits of rooibos tea and green rooibos, in particular, have only recently been 
recognised. Unlike the commonly occurring quercetin that has been extensively studied, 
relatively few studies on aspalathin have been done. Most of the studies have focused on 
the biological and pharmacological activities of rooibos. The present study is the first to 
investigate the percutaneous permeation and transport of aspalathin across Caco-2 cell 
monolayers. Green rooibos extracts contains various antioxidants, which undergo chemical 
and biological breakdown in the body. Further studies on percutaneous absorption of green 
rooibos extracts may be carried out to measure the total phenolic content of green rooibos 
after skin permeation, account for the degradation of the compounds, and evaluate the total 
antioxidant capacity of the permeants. Various vehicle systems carrying green rooibos 
extracts may also be investigated to enhance the absorption of rooibos tea.  
 
Many studies on the intestinal absorption of aspalathin can still be done to obtain a more 
comprehensive absorption profile. In this study, the apical-to-basolateral transport of 
aspalathin was investigated. The intestinal epithelial cells possess cellular activities such as 
enzymatic metabolism, carrier systems, and efflux mechanisms that affect absorption of 
drugs and molecules. By analysing basolateral-to-apical transport, metabolites, and cellular 
accumulation, the knowledge on the transport of aspalathin may become more complete.  
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ANNEXURE 1 
 
 
 
 
Prof J du Plessis 
Bussie 36 
Noordwes-Universiteit 
(Potchefstroomkampus) 
 
Geagte prof Du Plessis 
GOEDKEURING VIR EKSPERIMENTERING MET DIERE 
Hiermee wens ek u in kennis te stel dat u projek getiteld  “In vitro transdermale aflewering van geneesmiddels” 
goedgekeur is met nommer 04D08.  Let asseblief daarop dat pasiënte vooraf toestemmig moet gee en dat die weefsel nie 
vir ‘n ander doel aangewend mag word as dit waarvoor die pasiënt toestemming gegee het nie. 
Gebruik asseblief die nommer genoem in paragraaf 1 in alle korrespondensie rakende bogenoemde projek en let daarop 
dat daar van projekleiers verwag word om jaarliks in Junie  aan die Etiekkomitee verslag te doen insake etiese aspekte 
van hulle projekte asook van publikasies wat daaruit voortgespruit het.  U sal in Mei 2005 die dokumentasie hieroor 
ontvang.  
Goedkeuring van die Etiekkomitee is vir ‘n termyn van hoogstens 5 jaar geldig (volgens Senaatsbesluit van 4 November 
1992, art 9.13.2).  Vir die voortsetting van projekte na verstryking van hierdie tydperk moet opnuut goedkeuring verkry 
word. 
 
Die Etiekkomitee wens u alle voorspoed met u werk toe. 
Vriendelike groete 
ESTELLE LE ROUX 
NAMENS SEKRETARIAAT 
 
 
Etiekkomitee 
Tel (018) 299 2558 
Faks (018) 297 5308 
E-Pos dnvealr@puk.ac.za 
 
30 Augustus 2004 
 
 
POTCHEFSTROOMKAMPUS 
Privaatsak X6001, Potchefstroom, Suid-Afrika, 2520 
Tel: (018) 299-1111 • Faks: (018) 299-2799 
Internet: http://www.nwu.ac.za 
